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Editorial 
Is science 
above the law? 
Britain has dec ided to al low research on stem cells 
ob ta ined f r om human embryos, and Germany is to 
al low their impor t . This h igh l ights yet again the dif­
ferent approaches the 15 EU M e m b e r States take on 
these fundamenta l issues. It also shows the impor ­
tance and urgency of agreeing a European approach 
to such quest ions of 'science and society' ­ as the 
Commiss ion proposed last December. 
Life is n o w be ing object i f ied and marketed to such an 
ex ten t that ethical considerat ions risk be ing over­
looked. In a g lobal con tex t in w h i c h the w inner is 
o f ten the one w h o innovates fastest, there is a very 
real risk that in ­depth ref lect ion and publ ic debate on 
science and t e c h n o l o g y w i l l be b rushed aside 
because it stands in the way of 'progress' . 
N o b o d y w o u l d d ispute the need to supervise and 
cont ro l technological deve lopments w h i c h , t h o u g h 
they may be designed to solve specific problems, end 
up chang ing society as a who le . But h o w can w e con­
trol them? Society seems repeatedly to be presented 
w i t h a fait accompl i . Is this s imply because moral i ty is 
slower to change than reason? 
The decisions w h i c h are be ing m a d e increasingly 
reflect a tacit consensus a m o n g the 'experts ' ­ w h o 
c o m e main ly f rom the scientific and industrial c o m ­
muni t ies, and are b o t h judge and party to the affair. 
Science and industry are n o w in some sense laying 
d o w n the law. Our values are chang ing to keep up 
w i t h our scientific and technical knowledge . It is as if 
w e have given up t ry ing to cont ro l science and tech­
no logy democrat ical ly , and have finally accepted that 
society must adapt to techno logy ­ not vice versa. 
Bucking the t rend, last year the Commiss ion ini t iated 
a European d i a l o g u e on these d e v e l o p m e n t s , 
be tween representatives of research, and of society in 
the broadest sense. W e should no t , however , pre­
sume that the mat ter is n o w sett led. The debate wi l l 
go nowhere if these ideas are no t discussed, devel­
o p e d and conso l idated b o t h nat ional ly , and at an 
internat ional level. 
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Cancer, 
a European priority 
The Union's commitment 
On every front 
Q Spreading the 
cancer message 
Because clinical research 
is fundamental Prevention, detect ion, t reatment. . . 
Fundamental and clinical research are joining 
forces to f ight a disease whose varied and complex forms 
present a challenge to the efforts of scientists and doctors alike. RTD info looks at the 
progress of the latest research strategies and the vital work of cancer informat ion networks. 
Sixth Framework 
Programme (2002­2006) 
Following a political agreement at 
the Council of Ministers, and w i th its 
content and budget now set, the new 
directions taken are giving real shape 
to the European Research Area. 
INTERVIEW 
European research 
steers a new course 
European Research Commissioner 
Philippe Busquin sets out the main thrust 
and summarises the th inking behind it. 
O The home straight 
A preview of the Sixth Framework 
Programme due to be adopted this 
summer. 
Research 2002: 
the big November meeting 
All about the launch 
conference in Brussels. 
¡1 PORTRAIT 
The correct use 
of mathematics 
RTD info meets Giorgio Israel (La Sapienza 
University, Rome), expert on the history of 
mathematics, humanist and philosopher 
who is concerned about the aberrations of 
the technosciences, the misuse of 
mathematics and the foundations for a new 
rationality. 
ES Digest 
Opinions, Letters, News In brief, 
Publications, Diary, Calls for proposals. 
» 4 i l ENLARGEMENT 
Partners in excellence 
Thirty­four mult idiscipl inar/ centres of 
excellence in 11 candidate countries benefit 
f rom Union support. These new scientific 
and technological partners w h o wil l be 
strengthening the European Research Area 
are presented here complete w i th useful 
addresses. 
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Ü I OCEANOGRAPHY 
A floating phenomenon 
Polarstern, the star of German 
oceanography, spends its time sailing 
between the Arctic and the Antarctic. Its 
nine on­board laboratories are staffed by a 
succession of scientific teams studying such 
matters as climatology, marine biology, 
underwater geophysics and continental 
drift. 
INTERNATIONAL RESEARCH 
Indian resolve 
After its spectacular success in the 
comput ing sector, India is now turn ing to 
other high­tech fields, such as 
biotechnology. It has just signed a mutual 
scientific cooperation agreement w i t h the 
Union which marks a major departure f rom 
the usual not ion of development assistance. 
mia HEALTH 
The mobile phone: friend or foe? 
Are the electromagnetic waves emi t ted by 
mobi le phones and other everyday on­l ine 
technologies damaging to health? Scientists 
are unsure, the WHO is cautious, and the 
Union is backing new research on this 
problem for science and society. 
■ I l l INNOVATION 
Technology without borders 
The specialised experts f rom the IRCs, wh ich 
form a solid network throughout Europe, 
are helping SMEs w i th a high technological 
potential to conclude successful 
international cooperation agreements. 
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European research 
steers a new course 
On 28 January 2002 the Council of Ministers adopted a joint position -
taking into account the Parliament's opinion - on the Sixth Framework 
Programme. The priorities, implementing instruments and budgets 
have thus been decided. On the occasion of this key step/1) Philippe 
Busquin, Commissioner responsible for research and principal instigator 
of the programme, explains the thinking behind it. 
How would you judge the negotiat ing process 
between the Council, Parliament and Commission, 
which took up a large part of 2001? Do you recognise 
your initial project in the result? 
Philippe Busquin: When I became Research Commis­
sioner, just over two years ago, I proposed that research 
should be recognised as a vital area of Union policy. This 
was accepted and we have now set a new strategy within 
the in tegrated f ramework of a genuine European 
Research Area. The new framework programme was con­
sequently conceived wi th a completely different objective 
in mind than the previous ones and was designed above 
all to be a structuring instrument in the service of this 
objective. As it was innovative, there were many discus­
sions while it was being drawn up, but now that we are 
entering the final stage I feel that we have achieved very 
largely what we set out to do. 
First of all in terms of resources. The Commission had set 
a maximum overall budget of €1 7.5 bill ion, an increase of 
almost 1 7%. Agreement was reached on this amount 
w i thou t lengthy discussions and that is clearly a very 
important and significant achievement. 
Previous f ramework programmes prompted some 
pretty tough negotiating over the figures. Does that 
mean that the Union's political leaders now view 
research as more important than they used to? 
I believe that mobil isation in support of the European 
Research Area acted as a kind of trigger. Research is now 
well and truly on the Union's political agenda. In the past 
European research was certainly seen as necessary, but 
there was the tendency for it to occupy a somewhat sec­
ondary role, for example by justifying it in relation to the 
needs of the Union's other policy objectives. This notion 
of research providing 'services' has of course not disap­
peared entirely. 
But there is a new awareness that the knowledge-based 
society requires a much more pro-active, coherent and 
encompassing vision of the way Europeans manage this 
sector. At Union level, research needs its own policy and 
must set its own structured objectives which look to the 
future and are designed to reinforce its excellence. That 
changes the whole perspective. 
Which aspects of this new approach sparked the most 
in-depth debates? 
Two major policy directions we proposed were discussed 
at length . Firstly, the pr inciple of concentrat ing the 
research effort on selected priority fields. This requires a 
quite diff icult polit ical choice which had been largely 
(1) The final decision will be made alter a second reading at the European 
Parliament and when the rules for participation have been decided. 
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avoided in previous framework programmes, wi th the inevitable 
result that the research effort was spread too widely and too 
thinly. Concentration is essential if you want the added value of 
European research to integrate national potential and achieve 
the famous 'critical mass' required by scientific and technological 
progress in a global wor ld. 
I am pleased to say that the proposed priorities were all adopted 
The ERA'S drive for interaction 
European Research Area 
National 
programmes I i ^ 
The Union's Λ 
Framework Pro- -
gramme for RTD'J 
Open 
coordination 
European 
research policy 
European 
research 
organisations 
1 / 
The ERA aims to coordinate in an open manner the vital forces of science 
and technology in Europe and to incorporate them in a new Union-wide 
common research policy. 
and not in any way ' f ragmented', although the debate clearly 
served to modify certain initial options. 
The second difficult choice of direction concerned the adoption 
of new implementing instruments, namely the creation of net­
works of excellence, the putt ing together of integrated projects 
seeking to achieve ambitious objectives of strategic significance, 
and the possibil i ty of prov id ing European support for jo in t 
research initiatives by certain Member States. I see these three 
points as decisive as they wil l make it possible to realise the 
framework programme's potential to act as a catalyst wi th in the 
European Research Area. 
There were many discussions to present and explain these three 
new instruments. It is only right to question change, but at the 
same time there is a need to overcome fears, doubts and inertia. 
Did no t the fears and doubts arise out of giving up what one 
already has for the unknown, namely of losing the tradi­
tional 'clientele' of the f ramework programmes - most 
notably SMEs - which were used to 'tailor-made' projects 
which are less ambitious than those you are announcing? 
Indeed. And a perfectly clear compromise solution was found in 
this area. It was never my intention for the new instruments to 
absorb 1 0 0 % of the f ramework programme's resources. I 
wanted them to be there, and wi th significant resources, but a 
who le area of the f ramework p rogramme cont inues to be 
devoted to traditional missions of European research policy: 
measures in favour of SMEs, the mobil i ty of researchers - wi th 
increased budgets in both cases - research to support Union 
policies (especially at the Joint Research Centre), international 
cooperation, etc. There is, moreover, an increased commi tment 
to SMEs which will be allocated 15% of f inancing for thematic 
fields in addition to the specific measures for SMEs. 
I would add that it is wrong to think that centres of excellence 
and integrated projects will become the preserve of ' large' coun­
tries, ' large' laboratories or ' large' companies. That is not at all 
the situation if you look at the many major European projects 
past and present which small but highly efficient academic or 
industrial entities have either led or participated in. 
Also, the final stage in launching the new f ramework pro­
gramme will be the discussion of the 'rules for participation'. It 
is at this stage that we wil l define the project assessment and 
selection criteria as well as the way projects will be required to 
operate. 
Is the matter of the simplification of procedures going to 
come up for discussion again? They continue to be criticised. 
Personally, I believe that many things still need to be simplified 
and, above all, the consortiums which manage projects should 
be given more autonomy and flexibility. Of course one must 
ensure that European public money is not squandered, but too 
much bureaucracy ends up devouring one of the researcher's 
most valuable possessions: his t ime. At present for example, pro­
ject participants are asked to provide a detailed justification of the 
expected socio-economic benefits. It is almost as if they must 
draw up a business plan for their future innovation. Industry 
researchers often tell me that wi th in their company not even 
research using own funds is subject to such a rule. No t all 
research is undertaken wi th the certainty of success. I fear that 
this kind of criterion will end up awarding points to those who 
can write well! 
In your vision of the European Research Area you often stress 
the importance of fundamental research. Is it true to say you 
want to 'rehabilitate' it? 
Europe already supports fundamental research in many ways, 
although it is true that even the treaties themselves associate the 
framework programmes w i th ' f inal ' research wh ich benefits 
competitiveness and quality of life in Europe. But such objectives 
are not in any way incompat ible w i th the pressing need to 
develop fundamental research, qui te the contrary in fact. I 
believe that everybody is beginning to understand that we are 
entering a society in which the creation of new knowledge is 
increasingly essential to keeping the economy tu rn ing . The 
wor ld of industry understands this very well and is making 
increasing calls for 'upstream' support. 
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Apart from the launch of the new framework programme, set 
for the end of the year, how do you feel the European 
Research Area is shaping up? 
The framework programme is one instrument - representing just 
5 .4% of global research funding in the Union - in its realisation. 
A who le series of levers must be activated to generate this 
dynamic of a new European research policy. Some of these levers 
are already present in this programme - wi th necessarily l imited 
budgets - in the field of the mobil i ty of researchers, the develop­
ment of modern research infrastructures, dialogue between sci­
ence and society, and the coordination of national activities and 
programmes. 
On these and other points - and I am thinking in particular of 
intellectual property, the problem of the Communi ty patent, and 
venture capital - much still remains to be done and over the past 
two years I have launched actions and initiatives wh ich wil l 
strengthen during the coming months. 
But is not the coordination of national research the Achilles' 
heel of the European Research Area? 
I would not use that term, but I agree that it is a key concern. It is 
a matter of political wil l . The Commission has received a clear 
mandate to make a comparative evaluation of our research sys­
tems and this is now under way. We are proposing new instru­
ments for cooperation and coordination. The ball is now in the 
Member States' court. 
Also, in addition to the structural and organisational aspects of 
research, the Commission has laid two strong ideas on the table 
of the Spanish presidency. I believe these will give the European 
Research Area a clear and visible double goal, but it wil l take 
strong political commitment to achieve them. 
The first is quantitative. The Barcelona European Council in March 
2002 has set the ambitious objective of increasing the Union's 
global research expenditure to 3% of GDP by 2010, which is one 
and a half times the present amount. This major boost will help us 
catch up wi th the United States and Japan. I would stress that this 
is not a matter of increasing public expenditure but of private sec­
tor investments in research. Annual R&D expenditure by European 
companies currently lags behind that of their US competitors by 
€70 billion. 
Setting this objective is an ambitious challenge. Realising it is 
clearly not the job of national research ministers alone, but also 
depends on the commi tmen t of many government players 
responsible for fiscal and industrial policy in every country. 
The second objective is qualitative. We aim to create a Europe of 
knowledge and this clearly hinges on research and education pol­
icy. The dual mission of universities in this respect illustrates clearly 
to what extent these two fields are linked. All structures within the 
educational system must be involved in the training and mobility 
of researchers. 
Growth of the European research effort 
The budget for the 
Sixth Framework 
Programme is 17% 
more than for the Fifth 
Framework 
Programme. This 
represents a real 
growth of 9% after 
allowing for inflation. 
Calculated as an annual 
average compared with 
2001, support for 
research will receive 
3.9% of the Union's 
total budget over the 
coming years. 
Compared with total 
public expenditure on 
civil research by 
Member States, it 
represents about 6%. Increases in global budgets for 
RTD framework programmes 
What is your message to the research world at this particular 
moment in time? 
The first funds will be available under the framework programme 
at the end of 2002. I imagine this is an opportuni ty which will 
interest a lot of people. They should start preparing now. We 
know the priorities and the instruments. They should not wait 
until the procedures are finalised before starting to explore their 
future projects. 
I should like to address this message to researchers in the candi­
date countries in particular, because when it comes to adhesion 
research has a head start on other policies as the framework pro­
gramme is already completely open to them. They must know 
that they are an inherent part of the European Research Area. > 
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The home straight 
Following the political agreement of 10 December^1) between EU research 
ministers, the new generation of European programmes is fast becoming a 
reality. The budget and content of the new 2000-2006 Framework Programme 
have been set. The text is now with the European Parliament for a second 
reading and, providing that any proposed amendments do not require 
conciliation with the Council, the programme should be adopted this summer. 
With increased resources and an innovative approach, the main 
focus of the Sixth Framework Programme (FP6) 2000-2006 is to cre­
ate the European Research Area (ERA), for which it is one of the 
major tools. Its priority objective is to promote much greater inte­
gration of the European research effort and capacity and to enter a 
new era by implementing a coherent and concerted approach at 
Union level as a basis for developing genuine joint strategies. 
While ensuring that a number of traditional actions under previous 
Framework Programmes continue (such as the active participation 
of SMEs), the new programme - allocated €1 7.5 billion - is struc­
tured around the three main targets of concentrating and inte­
grating European research, structuring the European Research 
Area, and strengthening its foundations (see box). 
Seven priority fields 
The first and by far the most important of the target areas will be 
allocated three-quarters of the programme's total budget. 
In the interests of efficiency and to avoid the risk of duplication or of 
spreading the research effort too thinly, Union support will concen­
trate on seven priority fields (see table page 8). These priorities are 
areas of research in which Union action can provide real added 
value by encouraging the complementarity and multidisciplinarity 
of resources and capacities at transnational level. 
Six of these areas are crucially important for the competitiveness of 
the European economy: 
► research on genomics and biotechnology and combating major 
diseases (€2.2 billion, or one-eighth of the total budget); 
I information society technologies, allocated €3.6 billion (one-fifth 
of total resources); 
k research linked to sustainable development and the environment 
- energy, transport, global change and ecosystems (€2.1 billion); 
► nanotechnologies and nanosciences (fast developing and of major 
industrial significance), plus intelligent materials and new produc­
tion processes (€1.3 billion); 
► aeronautics and space (€1.1 billion); 
k food safety and quality - a field of competence in which the Union's 
prerogatives are vital (almost €700 million). 
New cooperation instruments 
Within these priority fields of research, three new instruments for 
allocating Community aid have been introduced to encourage 
greater integration. They are: 
-support for networking centres of excellence located in different 
countries - whether at universities, companies or research centres and 
organisations - with the aim of federating and integrating research on 
well-defined subjects in the medium or long term; 
- support for integrated projects involving a critical mass of scien­
tific and industrial partners with the focus on significant applica­
tions in terms of products, processes or services; 
- Union participation in specific cooperation programmes for sci­
ence and technology implemented jointly by several governments 
or national research bodies.<2> 
These new instruments will be implemented progressively/3' To 
ensure a smooth transition from previous programmes - in particu­
lar for SMEs - the Union will continue to support research and 
demonstration projects, coordination actions and concerted actions 
targeting more limited objectives, selected from the priority fields. 
The new structure of the Sixth Framework Programme 
Three main targets 
Integrating European 
research 
Structuring the ERA Strengthening the 
foundations of the ERA 
Basic principles 
Concentration on the 
priority fields of research 
and implementation of 
new instruments (sup­
port for networks of 
excellence, integrated 
projects and joint initia­
tives by bodies in certain 
Member States). 
To give horizontal 
policies (human 
resources, measures 
for SMEs, support for 
infrastructures) a struc­
turing effect through 
stronger links with 
national, regional and 
other European 
initiatives. 
Support for coordination 
of national programmes 
to ensure a coherent 
European research effort. 
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Society's expectations 
Although these priorities have an undeniable economic dimen­
sion, they are also at the heart of the new focus on relations 
between science and society. The life sciences and health, the 
information society, the environment, food safety... are all cen­
tral to the current questioning of scientific and technological 
development and the subject of public expectations. 
The final priority field - 'Citizens and governance in the Euro­
pean knowledge-based society', allocated over € 2 0 0 mill ion - is 
very clearly also a subject of importance in this respect. This will 
enable the Union to suppor t mu l t i - and transdiscipl inary 
research in the social, economic and human sciences, which 
contributes to the development of the knowledge-based society 
and the exploration of new forms of citizenship and governance. 
Structuring and strengthening 
In keeping wi th this science and society dimension, a budget of 
over half a bi l l ion euro wi l l be devoted to ant ic ipat ing the 
Union's scientific and technological needs and support ing com­
mon policies. 
In response to undoubted expectations on the part of the scien­
tific communi ty , another innovation is the inclusion of a budget 
post of nearly € 7 0 0 mill ion to help create and develop European 
scientific and technological infrastructures. 
Finally, more than € 3 0 0 mill ion wil l be set aside to help coordi­
nate national programmes and make them mutually accessible, 
thereby laying the foundations of one of the key aims behind 
creating the ERA. 
Adoption of the Sixth Framework Programme: 
timetable for the co-decision procedure 
Traditional support 
Previous 
steps 
During 2000 
• EC consultations 
Beginning of 2001 
• EC proposals to CM 
andEP 
End of 2001 
• EP's opinion 
(amendments) 
• Adaptation of 
the EC's proposals 
1st half 
of 2002 
• Common position of 
the CMC» 
• Second reading at EP 
• EC's opinion on EP's 
amendments 
2nd half 
of 2002 
• Scenario 1 : Approval 
by the CM<« 
(qualified majority if 
EC agreement, 
otherwise unanimity) 
of EP's amendments 
• Scenario 2: Convoca­
tion of Reconciliation 
Committee within 6 
+ 2 weeks; adoption 
of a joint project 
within 6 + 2 weeks. 
EC: European Commission - CM: Council of Ministers - EP: European Parliament 
(l)Adoptedon 10/12/2001, formalised on 28/01/2002. 
(2) Qualified majority decisions of the Council require 62 of the 87 votes cast, 
with the following weighting attributed to the Member States: F- D -1 -UK = 10 
votes each; ES = 8 votes; B-CR-NL-P = 5 votes; A- S = 4 votes; 
DK -IRL-SF=3 votes; L = 2 votes. 
The innovations introduced by FP6 have not, how­
ever, been at the expense of the tried and tested 
'horizontal ' programmes of its predecessors. The 
budget allocated to human resources and mobility, 
for example, a crucial field for the ERA, has been 
doubled to €1 .6 billion. Similarly, the financing of 
specific measures (cooperative and collective 
research) for SMEs is up by 2 4 % to € 4 5 0 mill ion. In 
the field of international cooperation, there will be 
an additional budget for specific actions to match 
the € 3 0 0 million already allocated under research 
actions. 
The Joint Research Centre will concentrate increas­
ingly on the implementa t ion and fo l low-up of 
Union policies (health safety of products, industrial 
risks, environment and sustainable development, 
nuclear safety, combat ing fraud, European refer­
ence system, technological foresight). The Centre 
will have a budget of just over € 1 billion, the same 
as under previous Framework Programmes. 
Finally, FP6 includes a budget of almost €1 .2 billion 
for research on nuclear safety, in line w i th the 
Union's responsibilities under the Euratom Treaty. 
(/) Formalised in the Council's common position of 28 
January 2002. 
(2) This new instrument responds in particular to the 
strategy of the ERA and the application, to date 
'dormant', of Article 169 of the Union Treaty. 
(3) The rules of participation proposed by the Commission 
for the application of new instruments are being examined 
by the European Parliament and Council. 
SMEs 
Apart from the specific measures 
in favour of SMEs. the target has 
been set to allocate SMEs 15% -
or about €1.7 billion - of the total 
available budget for research 
activities (priority fields). Under 
the previous programme their 
participation represented 10% 
of the budget. 
To find out more 
europa.eu.mt/comm/research/ 
nfp.html 
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Overview of new programme 
(Common position adopted by the Council on 28 January 2002 )0 
Types of activity 
1. FOCUSING AND INTEGRATING COMMUNITY RESEARCH 
Priority thematic themes of research'3' 
» GENOMICS AND BIOTECHNOLOGY FOR HEALTH 
- Advanced genomics and applications for health 
- Combating major diseases 
» INFORMATION SOCIETY TECHNOLOGIES 
» NANOTECHNOLOGIES AND NANOSCIENCES, 
MULTI-FUNCTIONAL MATERIALS AND NEW 
PRODUCTION PROCESSES AND DEVICES 
> AERONAUTICS AND SPACE 
> FOOD QUALITY AND SAFETY 
1 SUSTAINABLE DEVELOPMENT, 
GLOBAL CHANGE AND ECOSYSTEMS 
- Sustainable energy systems 
- Sustainable surface transport 
- Global change and ecosystems 
t CITIZENS AND GOVERNANCE 
IN A KNOWLEDGE-BASED SOCIETY 
Specific activities covering a wider field of research 
- Supporting policies and anticipating 
scientific and technological needs 
- Horizontal research activities for SMEs 
- Specific measures in support of international cooperation 
Direct activities of the Joint Research Centre 
- Food, chemical products and health 
- Environment and sustainable development 
- Horizontal activities 
- Technology foresight; reference materials and measurements; 
public security and combating fraud 
- Research training; access to infrastructures 
2. STRUCTURING THE EUROPEAN RESEARCH AREA 
- Research and innovation 
- Human resources 
- Research infrastructures 
- Science and society 
3. STRENGTHENING THE FOUNDATIONS OF THE EUROPEAN RESEARCH AREA 
- Support for the coordination of activities 
- Support for the coherent development of policies 
4. RESEARCH AND TRAINING IN THE NUCLEAR FIELD 
- Priority thematic fields of research 
- Controlled thermonuclear fusion 
- Management of radioactive waste 
- Radioprotection 
- Other activities in the field 
of technologies and nuclear safety 
- Activities of the Joint Research Centre 
TOTAL 
Millions of euro 
11 205 
1 150 
1 050 
810 
610 
700 
1 320 
760 
222 
40 
750 
90 
50 
2 200 
3 600C> 
1 300 
1 075 
685 
2 120 
225 
570 
450 
300 
212 
286 
262 
300 
1 630 
665(5) 
60 
280 
50 
890 
50 
290 
17500 
13 285«) 
2 655 
330 
1230 
17500 
% of total 
64.0 
6.6 
6.0 
4.6 
3.5 
4.0 
7.5 
4.3 
1.3 
0.2 
4.3 
0.5 
0.3 
12.6 
20.6 
7.4 
6.1 
3.9 
12.1 
1.3 
3.3 
2.6 
1.7 
1.2 
1.6 
1.5 
1.7 
9.3 
3.8 
0.3 
1.6 
0.3 
5.1 
0.3 
1.7 
100 
75.9 
15.2 
1.9 
7.0 
100 
(/) These figures are still subject to change during the final co-decision processes between the Council and European Parliament. 
(2) Including €600 million for international cooperation activities and any amount following decisions of the European Parliament 
and Council by virtue of Article 169 of the Treaty. 
(3) The aim is to allocate SMEs at least 15% of the total financial resources under this heading. 
(A) Including a maximum of €100 million for the continued development of Géant and GRID. 
(5) This amount includes €200 million for the continuation of the Géant and GRID projects. 
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Research 2002: 
the big November meeting 
Presenting a project? 
The Sixth Framework Programme for Research (FP6) (2002-
2006) will be launched between 11 and 1 3 November this year. 
To mark the occasion, a vast 'multiple dimension' conference 
will be held at the Palais du Heysei in Brussels. In addition to the 
traditional programme presentation and details of how to par­
ticipate, the event will also be a genuine forum for all those 
involved in research. A selection of some of the notable suc­
cesses of European research will also be presented to a wider 
public. 
► Every day there will be plenary sessions on the thematic pri­
orities of the Sixth Framework Programme, as well as the hor­
izontal aspects of the European Research Area, such as human 
resources and mobility, patents and intellectual property. 
Practical sessions will provide information on the rules and 
conditions governing participation in the Framework Pro­
gramme. 
> In addition to the Commission's programme there will be a 
participants' forum with a range of events designed and 
organised by researchers, associations and others on the sub­
jects of their choice in the very broad context of the debate 
between science and society (see box). 
» An exhibition with around 150 stands will present European 
research projects supported by the Union, with a specific area 
set aside for European and national research organisations. 
This opportunity to 'display' research will usefully complement 
the oral presentations and debates (see box). It should also 
help to promote the networking and integration of research 
activities in Europe. 
» Finally, there will be twice-daily 'press briefings'. Interviews 
can be arranged at the request of journalists and a press room 
will be at their disposal together with technical assistance for 
television crews. ► 
Are you working at a national or European research agency and is your 
research open to foreign researchers? If so, why not present your initiative at 
one of the 50 stands at the 'Sixth Framework Programme' exhibition? 
Proposals will be selected with the aim of covering a wide range of activities, 
areas and countries according to the following criteria: 
► their European dimension; 
t the quality and originality of the material to be exhibited; 
t potential interest to a wide public; 
» the project's impact on European research. 
Requests should be submitted to the Commission using the 
appropriate form which can be downloaded from 
http://europa.eu.int/comm/research/conferences/2002 or 
requested by e-mail at rtd-conference2002@cec.eu.int 
Closing date for applications: 31 May 2002. 
Announcement of stands allocated: July 2002. 
Organising an event? 
/orkshops, round tables, conferences and debates... Rooms with capaci­
ties ranging from 60 to 250 seats are available to those wishing to take part 
in the 'Participants' Forum'. Preference will be given to proposals on top­
ical subjects of interest to European research and society at large. Speakers 
should be good communicators and represent a variety of views and 
approaches in connection with a given subject. Young scientists are 
strongly encouraged to participate in these events, whether as organisers or 
participants. 
Proposals will be selected to cover a range of scientific and technological 
areas, on the basis of the following criteria: 
ι interest of the subject; 
> quality (competence and European/international scope) of the 
panel proposed; 
» relevance to European society; 
► contribution from European research or projects; 
» involvement of young scientists. 
Proposals must be submitted to the European Commission using 
a form which can be downloaded or requested by e-mail: 
» http://europa.eu.int/comm/research/conferences/2002 
» rtd-conference2002@cec.eu.int 
Closing date for proposals: 30 June 2002. Announcement of 
events selected: September 2002. 
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s the glass half empty or half full?' As ever, it all depends 
on how you look at it. After decades of cancer research, 
today progress at every level - prevention, detection 
and treatment - means that nearly one in two cancer 
patients is still alive five years after the initial diagnosis. 
'For many pathological forms, cancer should no longer be 
seen as an inevitably fatal disease but as a chronic and 
potentially reversible one,' stresses Shahid Baig, director 
of European research programmes. 
Yet the fact remains that oncologists are fighting a 
resilient foe which continues to take its toll: every year 
nearly 4 million new cases are diagnosed in Europe, and 
with 750 000 deaths it is the second cause of mortality 
among the EL) population. Although this high mortality 
rate is partly linked to the ageing population, one in three 
Europeans is hit by cancer before the age of 75. 
The main reason cancer is able to put up such resistance 
to researchers is that it is an extraordinarily complex dis­
ease. Behind its general mechanism (the uncontrolled 
division of a group of cells) are some very major differ­
ences. There are over 200 types of cancer, all with their 
own metabolic particularities about which we sometimes 
understand very little. For example, with testicular cancer 
the recovery rate is over 90%, while others can be more 
lethal (cancers of the lung, pancreas, ovaries, etc.). 
The fight against cancer therefore requires a multi-
pronged approach. Scientists are interested in every 
aspect of this family of diseases: its fundamental mecha­
nisms, the molecules able to influence it at various stages, 
the increased effectiveness of surgery, the effects of radi­
ation and hormone treatment, etc. 
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The Union's commitment 
Governments throughout Europe have adopted cancer as a research 
priority and it is also a field in which the pharmaceutical industry invests 
heavily. It is against this background that the Union has become 
increasingly active over the last decade or more, seeking to integrate 
research activities to create a synergy effect. 
The first field of cooperation is to support Europe­wide 
epidemiological studies to obtain a global view as a basis 
for developing and validating increasingly early and reli­
able methods of diagnosis. 
It is also essential to support the various transnational net­
works set up in the f ight against cancer. These guarantee 
the reliability and safety of scientific advances and enable 
all practitioners to benefit f rom the progress made and 
know­how acquired. 
The interdisciplinary approach 
Equally important are integration between fundamental 
research and clinical research as wel l as integrat ion 
between the disciplines (oncology, genetics, b iochem­
istry, biophysics, surgery, etc.) involved in developing 
new treatments. The barriers between these disciplines 
must continue to be eroded. 
The development of translational research is valuable in 
this respect, promot ing an interdisciplinary approach and 
the f low of information between fundamental researchers 
and clinical practitioners. This rapid move f rom funda­
mental research to clinical applications has become a pri­
ority, not only because it is the patient's r ight to have 
access to scientific progress but also because, in a highly 
competit ive international environment, a heavy price is 
paid for any delay. 
Coordination 
In the end, although hopes for a cure are increasing, it 
remains important to take into account the quality of life 
of patients who have to undergo often long and painful 
treatment. In this field too, oncology merits a European 
approach. 
Within the European Research Area, the f ight against can­
cer ­ identified as a priority by the 'Genomics and biotech­
nology for health' programme under the Sixth Framework 
Programme 2002­2006 ­ wi l l be waged by increasing 
coordination between centres of excellence in Europe. It 
is now accepted that no single country can work in isola­
t ion and that compared wi th the United States, for exam­
ple, where research by the National Institutes of Health is 
integrated nationally, European cancer research too often 
suffers f rom a duplication of research efforts. 
W '■■* - «Λ -"^«^ 
European 
Cancer Forum 
In May 2001, the Commission 
initiated the new European Cancer 
Forum (ECF) which meets several 
times a year. This provides 
continuous coordination between 
health officials responsible for 
financing research and the best 
scientific specialists with the aim 
of promoting complementarity and 
coherence between national 
research programmes both inside 
and outside Europe. The ECF is 
mainly interested in three 
aspects: 
t epidemiological monitoring of 
the disease and the adaptation 
of prevention and research 
strategies; 
> cooperation between European 
centres of excellence and more 
particularly their networking 
thanks to the new resources 
available under the EU's Sixth 
Framework Programme for RTD; 
and 
» rapid transfer of knowledge 
between fundamental research 
and clinical practice. 
Contact: 
Dr Shahid Balg, Research DG 
shahid. baig@cec.eu.int 
The above examp le shows the p repara t ion of a 
re­ in ject ion of l ymphocy tes t o inf i l t rate a t u m o u r , 
using a device w h i c h al lows cells t o be concen t ra ted 
and washed . 
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On every front 
Cancer is a formidable disease which takes many forms. This is why research must be 
active on many fronts. Traditional strategies - surgery, radiotherapy and 
chemotherapy - are improving all the t ime. Genetics and immunology are bringing 
new and innovative prospects. And new screening and detection methods are making 
it possible to get to grips with the disease at an increasingly early stage. 
At the most fundamental level, many projects adopt a genetic 
approach to the disease. Progress in this field has been extraor­
dinarily rapid and the recent sequencing of the human genome 
is a major step which should soon provide crucial keys to our 
understanding of tumour development. 
This is the aim of the research conducted by Lauri Aaltonen of 
Helsinki University who is coordinating research by several Euro­
pean teams on Peutz-Jeghers syndrome or PJS. This is a heredi­
tary disease whose symptoms include a distinctive face pigmen­
tation and, most importantly, a pronounced predisposition to 
Cellular signalling 
Sharing the same interest in the fundamental mechanisms of 
cancer, Jean-Marie Blanchard (Institut de Génétique Moléculaire de 
Montpellier - France) and his team have adopted another line of 
attack. They see cancer as essentially a 'cellular signalling' disease 
(see also box on the EMBL). Cells are constantly receiving very 
varied chemical messages which tell them what the body needs. 
The body may, for example, instruct cells to divide or to differ­
entiate a given type to compensate for cells destroyed due to 
wear or injury. On the other hand, it may instruct them to reduce 
Screening 
Image of a breast cancer obtained 
by tomovelography 
(ultrasonic scanner). 
© D.Dantchev/INSERM 
Biology 
Auer bodies in a leukaemic 
myeloblast showing the linear 
arrangement of the proteic mole­
cules which make up the crystal. 
© I.Breton Gorius/INSERM 
Surgery 
Operative field of a pancreatic cyst. 
©J.|.Duron/INSERM 
Medical imaging 
Cancer of the rectum. 
©J.J.Duron/INSERM 
the sporadic appearance of tumours. This research has identified 
the gene (known as LKB1 ) which mutates to cause PJS and marks 
a potentially very important discovery at the fundamental level. 
'LKB1 and the protein whose synthesis it controls evidently play 
a key role in the appearance of a whole family of very different 
cancers (intestine, breast, uterus, etc.),' explains Mr Aaltonen. 
'This would not be the first t ime that a very rare hereditary dis­
ease has provided valuable information on much more common 
pathologies.' Another Helsinki laboratory has succeeded in creat­
ing a strain of transgenic mice (knock-out mice) in which this 
gene has been destroyed and which it is hoped will yield a lot of 
new information. 
their activity or, if they serve no purpose, send them signals to 
self-destruct. The latter phenomenon - known as apoptosis or 
cellular suicide - was discovered less than five years ago and is the 
subject of intense study. It appears to be of extreme strategic 
importance: when cells behave in a way which is dangerous for 
the body and escape its control, the body's normal reaction is to 
prompt their auto-destruction. But in the case of cancer cells the 
instruction goes unheeded. 
'We have studied the action of a particular molecule in cellular 
signalling, TCFß,' explains Jean-Marie Blanchard. 'This is a mem­
ber of the growth factor family and acts as a kind of brake on cel­
lular division. It has two very important roles. It slows down the 
cellular cycle during the development of the embryo, thereby 
synchronising the creation of body tissue and organs -
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requesting the most advanced to wait for the stragglers if you 
like. This molecule also contributes to the normal elimination of 
certain tissue by means of apoptosis. Cancer cells manage to 
escape the action of TGFß. Once we have understood how, we 
can seek ways of correcting this malfunctioning.' 
Immunology 
Immunology is another field which has seen dramatic progress 
over recent years. Our understanding is improving all the time of 
the many cells which make up our defence system, their role and 
above all the hundreds of molecules they use to communicate, 
detect diseases and combat them. This progress has brought 
many applications in oncology. Although some have been cur­
rent practice for several years already, most of them are still at the 
experimental stage. 
What does this immunotherapy consist of? Contrary to popular 
belief, the immune system does not only defend the body 
against external intruders, such as bacteria or viruses, but is also 
able to detect tumour cells because they have mutated in a way 
This procedure, which will no doubt take some years to perfect, 
has one major benefit: in theory it also makes it possible to destroy 
any cancer cells lying elsewhere in the patient's body. We know 
that malignant tumours tend to form secondary tumours (see 
box) which have the same biological characteristics as the primary 
tumour. A melanoma which migrates to the liver, for example, 
retains its 'identity' which (at least in theory) would render it vul­
nerable to attack by the 'educated' white blood cells. 
A number of European laboratories ­ in particular those working 
on the Inducible melanoma model project ­ are trying to develop 
transgenic mice expressing 'human' tumours to study their char­
acteristics. 
Other strategies are also based on a stimulation of the immune 
system. For example, it was discovered that the well­known 
tuberculosis (TB) vaccine BCC also acted on cancer of the bladder. 
When injected directly into the patient it provokes an inflamma­
tion (in other words the mobilisation of natural defences) which 
helps the tumour to regress. Immune signalling molecules ­ such 
as interleukine 2 and interferons ­ are mainly used to treat 
melanoma and cancers of the kidney. 
« ■■■? m ■^■SjHsBJ 
Drug therapy 
© B.Loret/INSERM 
Fundamental research 
Study of cancero 
genesis. 
©I.Bara/INSERM 
which has altered their molecular 'ID'. There are, however, situa­
tions where the white blood cells which protect us find it difficult 
to recognise and destroy the enemies and need help in accom­
plishing their natural mission. 
One of the most promising strategies is implemented in two 
stages. First, the white blood cells are 'taught' to recognise the 
sick cells by putting them into contact with a tumour extract 
obtained by surgery. This is akin to 'vaccinating' the patient 
against his own tumour. These blood cells are then activated (or 
made aggressive) outside the body before being reinjected into 
the patient. If they are sufficient in number and the subsequent 
stages go according to plan, the white blood cells or lympho­
cytes will destroy the cancer cells. 
Tumours and cancers 
The term cancer applies to a family of diseases with the common feature of 
an anarchic proliferation of a cell population. They multiply until they 
form a mass known as a 'tumour'. A tumour may be 'benign', or in other 
words non­cancerous. In this case it is usually sufficient to simply remove 
it and the patient is cured. If, on the other hand, it is 'malignant', or can­
cerous, it is able to invade and destroy surrounding tissue. It can destroy 
the whole organ on which it is growing and possibly spread to neighbour­
ing organs. In some cases it can emit 'metastases' or small groups of prolif­
erating cells which leave the original tumour and circulate through the 
blood or lymphatic vessels before attaching themselves to new organs 
which are then also attacked. 
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Detection 
Another front of intense research activity is early and non-inva­
sive detection. Many cancers can only be diagnosed with cer­
tainty by means of a biopsy which involves removing cells for 
analysis. For this to be possible, a suspect zone must first be iden­
tified and localised, which can be problematic. Scientists are 
therefore seeking to develop molecular markers, or molecules 
associated with cancers, which could be detected by a simple 
blood test. As the markers are released at the start of the tumour 
process, this would save time when making the diagnosis and 
avoid surgery which can impair the patient's quality of life. This 
type of research is already very advanced for prostrate cancer as 
PSA enzymes indicating the presence of the disease were identi­
fied some time ago and European efforts are focusing mainly on 
standardising the detetection methods. But research in this area 
is also being conducted on cancer of the bladder, colorectal can­
cer and breast cancer. 
Surgery and radiotherapy 
Traditional strategies such as surgery and radiotherapy are also 
continuing to benefit from advances in knowledge. In particular 
the prospect of technology-assisted surgery, which would be 
much more precise and systematic, is becoming a reality. Medical 
imaging too has progressed rapidly over recent years, opening up 
vast possibilities for early diagnosis. 
This imaging should soon be able to assist practitioners, as illus­
trated by the results of research on breast cancer carried out by 
five European laboratories with EU support. 'We have developed 
a method of surgery guided by magnetic resonance imaging 
(MRI),' explains project coordinator Sylvia Heywang-Kobriunner 
of Halle University (DE). 'MRI - which is based on the circulation 
of the blood - enables us to detect suspect zones which may 
measure less than a centimetre in diameter. The other methods 
are much less sensitive. These lesions are not necessarily cancer­
ous so biopsies are necessary to find out. Our method makes it 
possible to insert a needle into the precise zone and draw out the 
contents. This can then be analysed or even eradicated com­
pletely - or in any event up to 3 cm in diameter - and all under a 
local anaesthetic.' 
Over the last three and a half years researchers have studied more 
than 500 lesions (about 25% of which were malignant), provid­
ing proof that the method works. 'This method offers many ben­
efits,' insists Ms Heywang. 'Less damage is done to the breast, 
there are cleaner margins around the tumour, and the risk of 
residual tumours is avoided.' > 
A feat of molecular engineering 
A diagram of the molecular 
structure of the 'Abl' protein. 
On the right, a simplified model 
in which the cord held by two 
fingers represents the cap 
structure and the heads of the 
red needles the location of the 
'switch' function. 
Last January, a team from the European Molecular 
Biology Laboratory (EMBL - Heidelberg, D), headed 
by Giulio Superti-Furga, announced the discovery of 
a molecular mechanism which is the cause of several 
types of lethal leukaemias. It has been known for sev­
eral years that these pathologies are caused by a 
genetic defect in the 'Abl' protein which plays an 
important role in the signalling of proteinic informa­
tion within the cell, in particular in controlling cellu­
lar division. Deficient Abl is comparable to a switch 
which you cannot turn off and which is constantly 
sending signals to cells to divide and thus spread. 
Researchers in the laboratory have succeeded in dis­
mantling the internal structure of artificial versions of 
normal protein, removing some of the constituents 
and then observing the ability to control the cellular 
division signal. They discovered that the 'switch 
effect' of the Abl proteinic molecule (when it is able 
to halt cell division) is linked to the presence of a cap 
structure, a sort of clamp that holds the cell con­
stituents in the right places and without which the 
switch becomes blocked in the 'on' position. 
This discovery of a mechanical model which explains 
the cause of the genetically defective Abl in some 
individuals is a breakthrough, opening the door to 
research on molecular engineering solutions to cor­
rect this absence of a cap structure. 
Giulio Superti-Furga, Cellzome AG 
Heidelberg (D) 
giulio.superti-furga@cellzome.com 
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Spreading the cancer message 
Collecting information on cancer is one th ing, communicating it 
effectively is another altogether. A number of organisations and networks 
are responsible for this vital mission. Sometimes specialised and 
sometimes more 'generalist', they provide researchers, practitioners and 
the general public wi th information on the latest advances in knowledge 
and techniques. The Cochrane network and the International Agency for 
Research on Cancer are just two examples. 
'Approximately 5 0 % of all cancer studies are not pub­
lished in the major journals and 2 0 % are not published at 
all,' stresses Christopher Williams, oncologist and mem­
ber of the Cochrane network. 'Researchers tend only to 
publish studies which produce results, and then princi­
pally in English. But research which has failed to produce 
results is also interesting - and not only to avoid duplica­
t ion. It can often inspire innovative variations.' 
The EU-backed Cochrane network consists of 14 groups 
in different countries. It aims to review systematically all 
therapeutic research on the treatment of cancer. 'It is no 
small task. It involves seeking out all studies - not only 
publications in English - on a given oncology subject.' 
In layman's language 
This work is essential for research. After all, what is the pur­
pose of undertaking costly and complex studies if others 
have already explored the field? The network's aim is to cre­
ate a genuine cancer library. 'We want our work to be 
accessible to the general public as well as professionals,' 
says Mr Williams. 'Our information, which generally con­
sists of about 50 pages of 'hard science', is prefaced with a 
very brief summary and another rather more detailed text 
in layman's language for the benefit of journalists and con­
sumer organisations. The library will be accessible on the 
Internet and everybody will be able to find information at 
the level they require.' 
Causes and prevention 
In Lyons, (F) the International Agency for Research on Can­
cer (IARC), an institution under the aegis of the World 
Health Organisation (WHO), specialises in research on the 
causes and prevention of cancer. The IARC regularly pub­
lishes articles and works for the benefit of specialists and its 
Internet site is a valuable source of information. 'We man­
age several cancer databases which are all accessible on 
the Web,' explains Nicolas Gaudin, the Centre's commu­
nicat ion manager. 'One of these keeps a register of 
monographs on all known carcinogenic agents. Another 
gives the figures of international and in particular Euro­
pean cancer registers - in other words the epidemiology 
of the disease, an essential tool in defining strategies to 
combat it. ► 
'The aim is for our work to 
be available to the general public 
as well as professionals. ' 
A network's network 
To find out more 
\ Cochrane Cancer Network and 
Cancer Library 
http://www.update-software, 
com/cancer/default.htm 
http://www.canet.org 
I International Agency for 
Research on Cancer 
http://www.iarc.fr 
http://www-dep.iarc.fr/ 
I International Union Against 
Cancer 
http://www.uicc.org 
Many other structures contribute to the synergy of strengths or the pooling of 
resources.") Some are highly specialised, such as the European Cancer 
Resources Bank (ECRB) which centralises a number of rare cancer cell strains 
and is a valuable tool for researchers. Others are of more general interest. The 
most well known is the International Union Against Cancer (UICC), based in 
Geneva. This has been spearheading the f ight against all forms of cancer for 
several decades now and organises conferences and training sessions. 
(/) See next article on the key role of the EORTC 
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Françoise Meunier, 
EORTC director-general 
for the past 10 years. 
With 2 500 voluntary practitioners in some 360 hospitals, 
the European Organisation for Research and Treatment of Cancer (EORTC) 
is a major spearhead in the global f ight against cancer. 
By organising rigorous clinical trials on a vast scale it has permitted major 
progress in the t reatment of the most varied forms of the disease. 
Because clinical 
is funda 
^mRi.wamwftS'i 
Double 
movement 
'Translational research' creates 
synergies between specialists 
involved at every stage of the 
disease, by ensuring a two-way 
information flow: from the 
fundamental to the applied 
and from the applied to the 
fundamental. 
The EORTC was set up 40 years ago by a handful of pio­
neering doctors working on a voluntary basis. It is not 
only one of the oldest experiences in creating a European 
research area but also one of the most successful. 'At first 
it was no more than a meeting of a select group of emi­
nent and visionary oncologists w i thou t any mandate, ' 
stresses Françoise Meunier, the organisation's director 
general. 'But given the urgency of the f ight against can­
cer they were aware that one country alone would never 
be able to cope and that it was crucial to make the most 
of the potential offered by European coordination of clin­
ical research.' 
Survival and quality of life 
What is EORTC's mission? To improve the treatment of 
cancer, by helping to develop new drugs as well as by 
defining optimal therapeutic strategies (surgery, radio­
therapy and chemotherapy) and the best possible use of 
existing methods. Epidemiology and prevention -
although also vital - are not within its scope: its chief task 
is to develop not just more effective treatment in terms of 
patient survival but also treatment which is able to 
improve their quality of life. 
The network develops and implements rigorous clinical tri­
als on vast numbers of patients throughout Europe. It is 
particularly necessary to have a wide field of experimenta­
tion for cancer - as combating it requires a mix of treat­
ments based on a multidisciplinary approach, unlike AIDS, 
diabetes or hypertension, for example, which are usually 
treated by drugs alone. In oncology, a new treatment can 
lead to questions about the optimal way to administer it 
and, when it is approved by the authorities, about how it 
would ineract with other treatments. The process of clini­
cal research is therefore crucial for implementing the 
results obtained in the laboratory and on animals. 
With or without industry 
To develop new medicines, it is very often necessary to 
work closely together with the pharmaceutical industry, 
which looks to the EORTC network to develop clinical trial 
strategies for innovative treatments and to test them at 
European level. The institution offers its formidable know-
how while retaining its independence in terms of 
analysing the data and guaranteeing the validity of the 
results. 
Lymphocytes in culture, taken from a tumour. 
© CMathiot/INSERM 
mental 
Although research progress 
is measured in terms of 
'cancer survival', EORTC has 
always been interested in the 
quality of life of patients who 
often have to undergo long 
and painful treatment. 
The development of reference treatments also involves carrying 
out a large number of tests which do not necessarily involve 
industry, and which could at times be contrary to its interests. As 
Françoise Meunier stresses: 'Drug manufacturers do not need to 
know, for example, whether a total or partial removal of the 
breast is preferable, whether radiation or surgery is best for pros­
trate cancer, or if a course of chemotherapy is best over four or six 
cycles. It is only so-called academic - in the sense of non-com­
mercial - clinical research which can answer these questions of 
therapeutic strategy. Around 70% of clinical trials carried out by 
the EORTC are without industry partnerships. That is why it is 
essential to continue funding this multidisciplinary clinical 
approach in Europe, carried out totally independently and most 
often on a voluntary basis.' 
A complex and painstaking approach 
How is a clinical trial conducted? One may want to determine, for 
example, whether or not it is useful to follow irradiation of a pros­
trate cancer with a course of hormone therapy. A trial of this kind/'' 
conducted in three distinct stages (see box), involves recruiting a 
large number of patients - sometimes several thousand - while 
respecting information and transparency requirements as well as 
international standards and national laws. Some are treated by the 
conventional means used to date and others by experimental treat­
ment. The two groups (selected by a procedure known as randomi­
sation) are carefully monitored to compare the results in terms of 
toxicity, survival and quality of life. 
Many difficulties must be overcome. An experienced and interna­
tional network with a sufficient 'critical mass' to identify therapeutic 
improvements - even if for just a few percent of the cases treated -
is vitally important. 
Ideally, several countries should participate in stage three to reduce 
the influence of local bias and recruit patients within a reasonable 
time frame. But the data must also remain homogeneous and the 
technical content and quality assurance procedures must be of the 
highest standard. 
Finally, any legal problems posed by the existence of different 
national legislation and ethical committees need overcoming. 'For 
· · 
(/) About 100 clinical trials of this kind are permanently under way under the 
aegis of the EORTC. 
EORTC, a multidisciplinary platform 
Much progress has been made over the past 40 years. Today, EORTC is a 
unique European institution, also recognised by the prestigious US 
National Cancer Institute (NCI) which, since 1974, has co-financed the 
analysis centre, home to its only office outside the United States. In addi­
tion to 'translational' and applied research, the organisation works with 
the computerised management of clinical data, quality of life, and the eco­
nomic value of therapies, statistics and methodology. 
And in the past decade, the headquarters has increased its personnel from 
28 to 134, including 100 university graduates. EORTC has its own found 
tion (Queen Silvia of Sweden is its president) and receives financial back­
ing from most of the European national leagues against cancer as well as 
the European Commission (for specific research projects), private donors 
and the pharmaceutical industry (to evaluate new drugs). Its network of 
2 500 members includes surgeons, oncologists, radiotherapists, immunolo-
gists and specialists from other disciplines. They all provide their sen 
free of charge. 
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2002, 
Europe against 
cancer meeting 
On the occasion of its 40lh anniver­
sary, EORTC is holding a 'Scientific 
Strategy Meeting' in Brussels from 
26 to 28 March 2002. The meeting 
will look at the current state of 
cancer research and seek to lay the 
foundations for future developments 
in clinical research by EORTC. 
To find 
out more 
www.eortc.be 
EORTC Communications Officer 
Samantha Christey 
sch@eortc.be 
Correlation between lung cancer, smoking and the genes 
iet\si 
ces VÎ' 
There is no longer any doubt 
about the causal link between 
smoking and lung cancer. 
However, smoking-related 
cancers could be influenced by 
genetic factors which affect the 
metabolism of the tobacco 
carcinogens. Some genes which 
code the enzymes involved in 
this metabolism could affect 
the cancer risk. 
(Study of the action of the CYP2D6 
cytochrome in 130 cases and 170 
control cases) 
© S.Benhamou/INSERM 
Tobacco 
consumption (g/day) 
Genetic susceptibility factor 
the same trial, seven different insurance policies must be 
taken out (with different premiums) due to the lack of har­
monisation of the legal obligations in different countries. 
The trial is sometimes finished before the legal problems 
concerning a country's participation have been sorted out. 
This evident drawback effects European innovation and 
competitiveness in treating cancer.' <2> 
The 'translational' approach 
It is sometimes difficult to persuade doctors to participate 
in clinical trials as respecting protocols can be very t ime 
consuming. 'For an individual cancer specialist working at 
a hospital it is often easier not to take part. An investiga­
tor has to spend more t ime wi th the patient, explaining to 
him all matters concerning the treatment of his illness, 
obtaining consent, setting up a team to carry out the trial, 
collecting and communicat ing the data, and sorting out 
legal and insurance matters to get the necessary approval 
to proceed.' 
Fewer than 5% of cancer specialists currently take part in 
clinical trials, approximately the same percentage as for 
cancer patients - despite the fact that t reatment in a 
research context (whether or not you are in the group 
receiving experimental treatment) can mean closer care, 
more rigorous treatment, an improved quality of life and 
better survival prospects. 
(2) All quotations are by Françoise Meunier. 
The three obligatory stages in a clinical trial 
Stage I - A new experimental treatment -pre- Stage II - T h e trials, generally including Stage III - If a stage II trial has shown that a 
viously tested in a laboratory on cell cultures 
and animals - is tried out on a small number of 
patients (between 10 and 40). Doctors seek the 
best way of administering it, in complete 
safety for the subject, and determine the max­
imum tolerated dose. 
between 40 and 80 patients, assess the effec­
tiveness of lhe experimental treatment tested 
on different types of cancer. 
treatment has an anti-cancer effect, the con­
ventional or standard treatment (the one 
most commonly applied in a given pathologi­
cal situation) is then compared with an inno­
vative treatment which it is hoped will prove 
more effective and/or less toxic. 
C A N C E R I RTD info N° 33 Apr i i 2002 19 
The fact is clinical research does not enjoy the same prestige as 
fundamental research. 'The researcher who discovers a new 
molecule is much more feted than the researcher who discovers 
in what doses and in what circumstances it must be adminis­
tered. The institutions which finance health care (social security, 
mutual associations, insurance companies, etc.) are also reluc­
tant to support clinical research, despite the fact that it can 
improve the management of health care systems, for example 
by reducing redundant or obsolete treatment, or by enabling a 
more efficient allocation of resources.' 
Fortunately, the fundamental/clinical divide is now closing and 
the move 'from mice to men' is attracting growing interest 
among decision-makers and the authorities. Removing this bar­
rier is moreover the principle behind 'translational research' 
which is developing rapidly due to recent progress in molecular 
biology and genomics. This approach involves bringing 
together specialists to cooperate at every stage of the process -
from the test tube to the hospital bed - while ensuring a two-
way information flow: from the fundamental to the applied and 
from the applied to the fundamental, thereby creating a synergy 
effect. 
A genuine 'clinical bank' 
This is the spirit which inspires EORTC. Once the trial results are 
obtained, the organisation seeks to disseminate them in a way 
which enables members of the medical profession in Europe and 
elsewhere to be continuously informed of the latest discoveries 
and the most promising strategies. It does so through scientific 
publications, conferences and courses. EORTC's analysis centre 
in Brussels also maintains a database on more than 1 30 000 
patients who have taken part in clinical trials over the past 
40 years. Every year, an additional 7 000 files are added to this 
data centre which many researchers consult regularly. ' EORTC 
is working on a project to compile a pan-European tumour bank 
with samples of tissue taken from cancer patients included in 
clinical trials,' explains Ms Meunier. 'The purpose is for 
researchers to be able to re-evaluate the tissue samples if 
one day new markers are discovered or new tests developed 
which make it possible to refine treatment and validate 
certain hypotheses by possible correlation with the patients' 
clinical data.' ► 
Clinical trials and ethics 
EORTC respects the ethical rules laid down in the Helsinki Declara­
tion, drawn up by the World Medical Association. This fundamen­
tal text is a moral charter whose objective is to provide recommen­
dations for doctors and others involved in medical research on 
human beings. It also includes studies carried out on personal data 
or non-anonymous biological samples. 
www.wma.net/f/policy/17-c_f.html 
The patients speak 
Although progress in research is often discussed in terms of 'cancer 
survival', EORTC has always been interested in a vital human 
aspect: the quality of life of patients. Some treatments or strategies 
improve patient comfort a great deal, even if they have no effect on 
the cancer's development. The evaluation of quality of life is based, 
in particular, on 'validated articles'. In-depth questionnaires - with 
a common section for all patients and another which is specific to a 
particular cancer type - are available in 42 languages and enable 
patients lo express how they feel before, during and after the trial. 
These documents are valuable instruments developed by the organ­
isation and are available to practitioners and researchers. 
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The correct use 
Professor of the history of mathematics at the University of Rome's 
La Sapienza, Giorgio Israel is concerned about the way 
he beljeves mathematics is being hijacked by the technosciences. 
Selected 
bibliography 
I The Invisible Hand. Economic Equi-
librium in the History of Science 
(with B. Ingrao), Cambridge, 
Mass., The MIT Press, 1990. 
► // Mondo come gioco matematico. 
John Von Neumann, scienziato del 
Novecento {with A. Millan Gasea). 
La Nuova Italia Scientifica, 1995. 
I La mathématisation du réel. Essai 
sur la modélisation mathématique, 
Paris, Le Seuil, 1996. 
► Le jardin au noyer, pour un 
nouveau rationalisme, Paris, 
Le Seuil, 2000. 
t The Biology of Numbers. The Corre-
spondence of Vito Volterra on 
Mathematical Biology 
(with A. Millan Gasea), Basel, 
Birkhäuser, 2002. 
Giorgio Israel is a member of 
the International Academy of the 
History of Sciences, the executive 
committee of the International 
Commission on History and 
Mathematics, and director of the 
University of Rome 'La Sapienza' 
Centre for Research on the 
Methodology of Sciences. He is a 
former lecturer at the Ecole des 
Hautes Etudes en Sciences 
Sociales (Paris). 
Contact: 
giorgio.israel@uniromal.it 
www.mat.uniromal.it/people/ 
israel 
Rome, La Sapienza - Department of Mathematics: One 
would imagine this Mecca of cerebral abstraction, wi th in 
one of Europe's most prestigious universities, to be inhab­
ited by some rather austere intellectuals, which is why 
meeting Giorgio Israel comes as something of a surprise. 
At the age of 57 and wi th a young son on w h o m he clearly 
dotes, he is a man of many interests, turning his inquiring 
mind to such matters as the state of the wor ld , contem­
porary humanism and the history of science and its sub­
servience to technology. 
Giorgio Israel is not just a mathematician - he is also a 
recognised historian. He specialises in exploring the disci­
pline's long secular development and the relationship 
between mathematics and other sciences. In particular, 
the professor is concerned at the way it is being distorted 
in certain disciplines. He accepts that the computer is a 
marvellous tool which, besides opening up extraordinary 
possibilities for scientific research, is now irreplaceable -
just as the pen used to be for wr i t ing. But just as a hand 
and a pen left to themselves cannot wri te anything intel­
ligible, so the use of the computer must be governed by 
conceptual structures. 
Correlation is not a law 
Giorgio Israel draws his examples from two fields in which 
he has made a particular study of 'mathématisat ion'. 'The 
distortion is particularly evident in economic and life sci­
ences. The ever-growing memory, calculating capacity 
and speed of computers today makes it possible to 
process vast quantities of data and arrive at correlations 
and models which are accepted as scientific laws. But a 
correlation is not an explanation and nor is it a law, and 
the role of science - as forged during the great adventure 
of mathematical physics, f rom Newton to Einstein - is first 
of all to explain the structure of phenomena. 
'When economists reduce the funct ioning of society to 
equations, they are failing to respect scientific rigour, he 
believes. 'They forget that their science is placing a vital 
Giorgio Israel - 'The worst thing would 
be to believe that scientific rationality is reason's 
sole means of perception.' 
variable, namely human freedom, in a concrete historical 
context , and that this cannot be "ma themat i c i sed " 
because historical t ime cannot be reduced to mathemat i ­
cal t ime. ' 
The distortion is no doubt less severe in biology. By seek­
ing correlations one can imagine hypotheses and that is 
certainly not wi thout purpose. 'But an all-powerful math­
ematics is nevertheless dangerous as the results are largely 
uncertain and often contradictory. In many cases there is 
a tendency to ignore the negative results which could 
weaken the hypothesis. A particularly sensitive field is at 
stake here: scientific probity. ' 
Finding the causes 
This tendency to use mathematical models to shore up 
the ' t ru th ' rather than to analyse the phenomena and 
explain the facts is particularly worry ing. 'In his Principia 
Mathematica, Newton states tha t the mission of the 
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of mathematics 
philosophy of nature is to seek causes,' 
explains Giorgio Israel. He believes that we 
are now witnessing the disappearance of this 
unitary system of knowledge which expired 
with the theory of relativity and quantum 
physics. 'Today, only physics seems still to be 
bound to this scientific model, but it is no 
longer at the heart of big science, being less 
attractive to younger generations who prefer 
other fields close to the life sciences or busi­
ness sciences. Research in mathematics is 
drying up. A number of my colleagues have 
adapted to this by undertaking practical 
research with immediate applications, for 
which there is a demand.' 
The technoscientists 
Giorgio Israel believes that the reason for the 
change is our immersion in the world of 
technoscience. The compression of two 
terms into a single neologism is significant: 
science and technology are now one. We 
have come a long way from the philosophy 
of the Enlightenment when scientists could 
be viewed as society's rational guides. 
Technoscience embodies a split personality: 
half researcher, half businessman. 
'What we are witnessing at present in the 
field of cloning is very symbolic. To my mind 
this race to create life is madness. It is a com­
plex problem with implications which should 
not be taken lightly. We are seeking to intro­
duce into nature disturbing factors and new 
organisms, the effects of which are still 
unknown.' 
In addition, anything related to the engineer­
ing of life can already pose questions of iden­
tity which our society seems to want to 
ignore. The case of the surrogate mother is 
one example. 'The child will have two moth­
ers. Scientists should take time to reflect in 
the face of such a situation as it is a problem 
of concern to us all, one which for the first 
time in history calls into question the cement 
which has always held humanity together, 
namely parental ties.' 
Dostoevsky and Einstein 
In the face of the ambiguous directions taken 
in the name of science, Giorgio Israel opts for 
answers founded on reason. The title of his 
latest work (Le jardin au noyer, pour un nou-
veau rationalisme) suggests, however, that to 
his mind reason is not a simplistic concept: 
'The worst thing would be to believe that sci­
entific rationality is reason's only means of 
perception. For me a novel by Dostoevsky is 
just as much a manifestation of rationality as 
a work of history or psychology. And science, 
which advances by means of trial and error as 
well as seemingly irrational intuition, is just 
one form of many forms of knowledge.' > 
Opposed to placing too much faith in 
artificial intelligence, Giorgio Israel 
likes to cite this anecdote as related by 
the great philosopher of science Karl 
Popper (who died in 1994). 'In a famous 
lecture, Alan Turing*1» said: Tell me what 
you think a computer cannot do and I will 
make one which can do exactly that. I 
answered him by letter: what do mean 
by tell me? Perhaps I need to give you a 
description, because in that case it 
would be an easy challenge. Clearly 
what must be avoided is the description 
itself. There is one thing a computer cer­
tainly lacks and that is initiative. And I 
do not know how one can describe ini­
tiative. Your challenge is therefore a 
bluff. Yet any child and even any puppy 
is full of initiative.' 
(1) Alan Turing (1912-1954) was one of the 
pioneers of the computer and a major advo­
cate of machine intelligence. 
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Calls for proposals 
EOI: express your interest 
In anticipation of the Sixth Framework 
Programme (FP6), at the beginning of 
April the Commission will be launch­
ing a new call for expressions of interest 
accessible to all Europe's research play­
ers. The purpose is to permit the most 
targeted preparation possible of pro­
grammes designed to implement the 
strategic priorities defined in the seven 
thematic fields adopted for the inte­
gration of research (see page 8). 
Ideas submitted must relate to scien­
tific and/or technological proposals 
which correspond to the implementa­
tion of two of the new instruments 
under FP6: the networking of centres 
of excellence and the implementation 
of integrated projects guaranteeing a 
critical mass for research. 
This call for expressions of interest is set 
to close on 5 June 2002, although the 
date has not yet been confirmed. 
Check the Research site for updates. 
europa.eu.int/comm/research/index_ 
en.html 
Science and society: activities in 2003 
and scientific communicators, and 
the organisation of events as part of 
European Science and Technology 
Week 2003. 
www.cordis.lu/improving/calls/rpast 
200201.htm 
There is one month's grace for the 
call for proposals (the last under the 
Fifth Framework Programme) in the 
field of Increasing public awareness of 
science, which will now close on 15 
April 2002 and not 15 March. The call 
concerns actions relating to dialogue 
with the public, the role of the media 
Objective 3%.. . 
Up from 1.9% to 3% of GDP by 2010! This represents a 50% increase in the 
Union's total research effort ­ mainly achieved by relaunching private invest­
ment in R&D. The ambitious objective proposed by Research Commissioner 
Philippe Busquin (see interview page 5) has been endorsed by the European 
Council of heads of state and government held in Barcelona under the Span­
ish presidency on 15 and 16 March 2002. 
At the beginning of February the informal Council of Research and Industry 
Ministers, meeting in Gerona (ES), decided that setting such a target would be 
an effective means of enabling Europe to make up for its innovation deficit. 
Twenty days later, at a meeting of the ECOFIN Council in Brussels ­ attended 
by Commissioners Pedro Solbes Mira (economic and monetary affairs), Frits 
Bolkestein (internal market) and Michaele Schreyer (budget) ­ the Member 
States approved a set of very concrete recommendations to increase private 
investment in research and improve Europe's capacity to innovate. 
Mobility: Wise Moves 
C|S 
wise t 
The transition from the Fifth to the 
Sixth Framework Programme does 
not mean that mobility is coming to a 
halt. In the period to 2005, the Euro­
pean Commission will continue to 
offer financial assistance to young 
NIS researchers 
The INTAS programme (East­West sci­
entific cooperation programme link­
ing the Union and the New Indepen­
dent States of the former Soviet 
Union) offers young researchers from 
the Central and Eastern European 
countries interesting support in the 
form of grants to visit Western institu­
tions. The closing date for applica­
pre­ and postdoctorate researchers in 
all scientific fields for three types of 
activity: participation in high­level 
scientific conferences; visits to univer­
sity or industrial research centres or 
institutions (Marie Curie fellowships); 
and access to specific research train­
ing networks. 
Interested? The Wise Moves site on 
the CORDIS server gives access to 
three databases with details on all 
current calls. 
www. cordis, lu/improving/opportunities 
tions is 25 April 2002 for grants 
awarded in November 2002. There is 
also a periodic call open for 
researchers seeking to attend scien­
tific conferences (next selections: 
15/04/2002, 15/07/2002 and 
15/10/2002). 
www.intas.be/mainfs.htm 
On the eve of the European Council, two of its members, Tony Blair (UK) and 
Wim Kok (NL), addressed a joint letter to Spanish Prime Minister José Maria 
Aznar, holder of the Union presidency until June. In it they present a document 
entitled Overcoming the European Paradox which sets out practical measures for 
the Community and the individual Member States designed to enable Europe 
to overcome its weakness in exploiting its excellent research potential. The two 
heads of government also call for the concept of the European Research Area to 
be enlarged to include increased promotion of innovation, especially in the 
field of implementing intellectual property rights and by strengthening links 
between the world of research and economics. 
Research is therefore increasingly at the centre of Union strategies, as is likely 
to be confirmed by the Barcelona European Summit. The 3% target ­ which 
would bring Europe up to the level of its US and Japanese competitors ­ could 
then become the motor behind the European Research (and Innovation) Area 
over the coming decade. 
Brochures, leaflets, 
reports, studies 
t The European Research Area ­
A common strategy for science and 
technology in the service of society 
­ Brochure ­ Available in DE, EN, 
FR research@cec.eu.int 
I Imagine, Show, Discuss ­ European 
Science and Technology Week ­
Brochure ­ Available in DE, EN, FR 
research@cec.eu.int 
I Europeans, science and technology 
­ Survey report ­ Special edition 
of RTD info on the results of the 
Eurobarometer survey ­ Available 
in DE, EN, FR research@cec.eu.int 
AND TECHNOLOGY 
Survey Í "**> 
findings r « Ä 
*5» 
Publications 
I European bio­entrepreneurs. 
Examples of start­up companies in 
the biotech sector ­ Brochure 
indridi.benediktsson@cec.eu.int 
► Local initiatives to combat social 
exclusion - Leaflet 
marthe.leonidou@cec.eu.int 
k European research in the 
stratosphere 1996-2000 Study 
georgios.amanatidÌ5@cec.eu.int 
I Scientific policies in the European 
Union: integrating the gender 
dimension, a factor for excellence -
Report 
nicole.dewandre@cec.eu.int 
t Photovoltaics: an energy resource 
for the European Union - Brochure 
helpline-energy@cec.eu.int 
I Research and Technological 
Development Activities of the Euro­
pean Union - 2001 Annual Report 
(downloadable) 
europa.eu.int/comm/research/ 
report2001.html 
Project reports 
l European defence restructuring: 
military and public view - EUR-OP 
► Reconstructing the means of 
violence: defence restructuring 
and conversion - EUR-OP 
I The restructuring of the European 
defence industry - EUR-OP 
► Socio-economic projects in energy 
and environment - domen ico. 
rossetti-di-valdalbero@cec.eu.int 
» Reviewing flexibility. A systems 
approach to vocational education 
and training-EUR-OP 
I Antimicrobial resistance research -
EUR-OP 
t Unconventional medicine 
ursula, holler@cec.eu.int 
I Generic RTD activities and research 
infrastructures -
manuel. hallen@cec. eu. int 
I Impact of major transport 
infrastructures on the quality 
of urban shape - EUR-OP 
t Meteorology during peak pollution 
episodes - EUR-OP 
► Radar hydrology for real time flood 
forecasting-EUR-OP 
I Wood assess project. Systems and 
methods for assessing conservation 
state and environmental risks for 
outer wooden parts of cultural 
buildings-EUR-OP 
► Life cycle assessment on forestry 
and forest products - EUR-OP 
Conference reports 
I Governance: an academic contribu­
tion - Published under the auspices 
of the Italian Embassy in Brussels -
ambit.bxl.scientifico@attglobal.net 
I Groundwater ecology - A tool for 
management of water resources 
- EUR-OP 
» Review of heat treatments of wood 
- EUR-OP 
The publications mentioned are a 
selection. A complete list of 
scientific publications from the 
RTD programmes is placed on 
the research website every two 
months: 
europa.eu.int/comm/research/ 
pub_rtd.html 
Printed publications accompanied by the mention of an e-mail address are 
free and can be obtained by sending a message to the address given. 
EUR-OP (Office for Official Publications of the European Communities) 
means that the printed versions must be purchased. To order copies 
please visit the website at: eur-op.eu.int/general/en/s-ad.htm 
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Research meetings under 
the Spanish presidency 
» Poverty­related diseases: Euro­
pean platform on clinical trials ­
19­20/4/02 ­ Barcelona 
» European ethical group ­
19­20/4/02 ­ Barcelona 
I Social sciences: European policies 
and institutions ­ 6­7/5/02 ­
Barcelona 
t Strategic platform for research 
on biodiversity ­12­14/5/02 ­
Almería 
I Future research priorities ­
Organised by the IPTS­JRC ­
13­14/5/02­Seville 
t Science and the environment: 
accepting research risks to reduce 
societal risks ­
30­31/5/02­Murcia 
► Technologies for sustainable land 
and sea transport - 4-6/6/02 -
Valencia 
t Women and science - 5/6/02 -
Madrid 
I The ERA and the Sixth Frame­
work Programme: research in 
Europe's most outlying regions -
24-25/6/02 - Canary Islands 
Calendar of Evei 
/ 
H nuti mu··. » iBitfrrrnda* 
www.cordis.lu/spain/events.htm 
presidencia.sepocyt@mcyt.es 
Other events 
I Third European Forum for Innova­
tive Enterprises - 8-9/4/02 -
Stockholm (SE) 
www.thirdforum.org/ 
I The Physics Congress 
02 - 7-11 /4/02 - Brighton (UK) -
www.iop.org/ 
I G.ite2Giowlh annual conference -
9-10/4/02-Stockholm (SE) 
www.e-unlimited.com/ 
» Drug Discovery Technology -
Europe 15-18/4/02 - Stuttgart (DE) 
www.drugdisc.com/stuttgart/ 
» Intertraffic 02 - 15-18/4/02 -
Amsterdam (NL) 
www.show-info.nl/intertraffic/ 
t IFAT 02 - waste disposal and the 
environment - 1 3-17/5/02 -
Munich (DE) 
www.ifat.de/english/ 
► Cultural Heritage Research: 
a Pan-European Challenge -
16-18/5/02 - Cracow (PL) 
www.heritage.ceti.pl/back-
ground.html 
» 5th International Congress and 
Trade Fair 'Water: Ecology and 
Technology' (ECWATECH) -
4-7/6/02 - Moscow (RU) 
www.sibico.com/ 
► Dissemination Conference of 
Current European Research on Rice 
6-8/6/02 - Turin (IT) 
eurice.elu@spm.it 
» Biomass for Energy - Industry and 
Climate Protection - jointly 
organised by ETA-Florence, WIP-
Munich & BWE - 1 7-21 /6/02 -
Amsterdam (NL) munich.de/ 
conferences/biomass/ 
amsterdam_02/amsterdam.html 
I Towards an integrated infrastruc­
ture for measurements -
18-19/6/02 - Warsaw (PL) 
europa.eu.int/comm/research/ 
growth/warsaw/indexen.html 
» Irilei 02 - Research and Scholarship 
in Integration Processes: Poland-
USA-EU - 19-22/6/02 - Lodz (PL) 
¡nter02@krysia.uni.lodz.pl 
I New trends in water and environ­
mental engineering for safety and 
life: eco-compatible solutions for 
aquatic environments -
24-28/6/02 - Capri (IT) 
www.capri02.com 
»1st World Wind Energy Conference 
and Exhibition - jointly organised 
by ETA-Florence and WIP-Munich 
2-6/7/02-Berlin (DE) 
www.world-wind-conference.org/ 
» INTERFORST (international Trade 
Fair For Forestry And Log Timber 
Technology) - 10-14/7/02 -
Munich (DE) 
www.interforst.de/english/ 
I International Conference on Project 
Management - 31 /07 -
02/08/02 - Singapore (ML) 
www.ntu.edu.sg/MPE/ 
ProMAC02/ 
t Kansai' 02 - Integrating Regional 
and Global Initiatives in the 
Learning Society - 12-15/8/02 -
Kyoto (JP) 
in3.dem.ist.utl.pt 
t Conférence internationale sur 
l'échantillonnage de l'ADN - Inter­
national DNA Sampling Conference 
5-8/9/02 - Montreal (CA) 
www.humgen.umontreal.ca/ 
conference/fr 
t Eastern Enlargement of the EU -
Implications for development 
strategies and development co­
operation in the 21st Century 
19-21/9/02- Ljubljana (SL) 
www.eadi.org/generalconfer-
ence.htm 
k International Conference on Soils 
under Global Change - a Challenge 
for the 21st century 
September 02 - Constanta (RO) 
m.dumitru@icpa.ro 
t PV for Europe - Conference and 
Exhibition on PV Science - Technol­
ogy and Application jointly 
organised by ETA-Florence and WIP-
Munich - 7-11 /10/02 - Rome (IT) 
www.wip-munich.de/ 
conferences/pv/rome_ 
02/index.html 
► Colour of Ocean Data - Organised 
by the Flanders Marine Institute -
25-27/11/02-Brussels (BE) 
www.vliz.be/en/acruv/cod/ 
» Genomics and Forest Tree Stress 
Tolerance Short Course -
Course - 11/02 - Chania (GR) 
adoulis@maich.gr 
t RDT info, Revista de la Investigación 
Europea 
europa.eu.int/comm/research/rtd-
info es.html 
Beginning with the current issue, 
a Spanish version of the articles 
published in RTD info will be 
available on the Research DCs 
Europa site. The complete issue 
can be downloaded in pdf 
format. 
► Science and society in Europe -
How to bridge the gaps? 
europa.eu.int/comm/research/ 
press/200 l/pr0612en.html 
This Research DG site gives the 
full results of the Europeans and 
science Eurobarometer survey car­
ried out at the request of the 
European Commission (see also 
the special edition of RTD info as 
mentioned under Publications). 
» The Union and space policy 
europa, eu. int/comm/space/ 
index_en.html 
This new site dedicated to space 
provides details of all aspects of 
the Union's initiatives in the field 
of space, in particular, thanks to 
the new coordination links intro­
duced by the European Space 
Agency. 
I SciDcv.Nel: science 
for development 
www.scidev.net/ 
SciDev is a remarkable site set up 
by the scientific team from the 
magazine Nature, with support 
from the British Welcome Trust. 
The idea was born in Budapest in 
1999 at the world conference on 
science organised by Unesco and 
the International Council for Sci­
ence (ICSU). Since it was 
launched in December 2001 it 
has operated as an independent 
gateway providing quality infor­
mation and debate of interest to 
New on the Web 
researchers, policy-makers and 
NGOs who want science and 
technology to be used to help 
developing countries. 
I Industry seeks women researchers 
europa.eu.int/comm/research/ 
science-society/women/wir/ 
index en.html 
Public or private research? In 
both cases women play an insuf­
ficient role. The Commission's 
Women and science group has to 
date mainly studied the role of 
women researchers in public 
institutions. A group of experts 
has now embarked on similar 
studies in the private sector. As 
part of the new Science and Soci­
ety Action Plan they will study 
the situation of women in Euro­
pean industrial research and 
identify new avenues to be 
explored to increase their pres­
ence. For the latest develop­
ments, go to 
http://www.cordis.lu/rtd2002/ 
science-society/women, htm 
The latest news on 
Europa/Research 
> Decoding the genome of the 
Schizosaccharomyces pombe yeast 
is opening the way to major med­
ical developments - 21 ,'2/02 
europa.eu.int/comm/research/ 
press/2002/pr2002en.html 
» ECHO project: high-tech research to 
save and archive documentaries on 
Europe - 7/2/02 
europa.eu.int/comm/research/ 
dossier/do0702fr.html 
t Improving mobility in the city 
through research (European 
Parliament) - 30/1 /02 
europa.eu.int/comm/research/ 
press/2002/3001 en.html 
► Ozone and UV over Europe: no sign 
of improvement - 22/1 /02 
europa.eu.int/comm/research/ 
press/2002/2201en.html 
» Descartes Prize 2002 - €1 000 000 
for outstanding scientific 
achievements - 21 /12/01 
europa, eu. in t/comm/research/ 
press/2001 /pr2512en.html 
► Stem cells: Statement from the 
European Life Sciences Group -
20/12/01 
europa, eu. in t/comm/research/ 
press/2001/pr2112en.html 
t Commission establishes Group of 
scientific experts on the fight 
against biological and chemical 
terrorism-12/12/01 
europa.eu.int/rapid/start/cgi/ 
guesten.ksh?p_action.gettxt=gt& 
doc=IP/01/1810\0\RAPID&lg=EN 
(¡display= 
I Towards a Common European 
Railways Research Strategy: EU 
Commission Launches European 
Rail Research Advisory Council 
(ERRAC) - 26/11 /01 
europa.eu.int/comm/research/ 
press/200 l/pr261 len.html 
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Partners in excellence 
With Union support, 34 multidisciplinary centres of excellence 
in 11 candidate Member States are now fully operational. 
Together they form an advanced platform for integrating their 
scientific and technological potential in the European Research Area. 
There is much to criticise in the regimes 
which for decades shackled Central 
Europe's former people's democracies 
behind the Iron Curtain. But at least these 
systems had 'faith' in science, even if it 
was often used as a tool in the service of 
their image and politics. The denationali-
sation in the decade which followed the 
fall of the Berlin Wall dealt a heavy blow 
to this scientific know-how and the repu­
tation for scientific excellence in these 
countries suffered terribly. 
Today it is a major European challenge to 
restore this research potential, particu­
larly in the light of their future Union 
membership. At a conference in Budapest 
in March 1997, Jürgen Rüttger, German 
research minister at the time, suggested 
that the Fifth Framework Programme 
should include the creation of a network 
of centres of excellence covering the can­
didate countries. 
Developing links, 
increasing attractiveness 
Following last year's call for tenders by 
the Commission as part of its policy on 
'international research cooperation, 34 
scientific or technological institutions'') 
were selected (out of 184 applicants) to 
lay the foundations of such a network. 
Today the Union actively supports this 
network in developing the scope and 
range of its activities. The total aid pack­
age of €24 million has been allocated to 
the individual centres according to the 
actions they propose on developing 
external links and increasing their attrac­
tiveness while, at the same time, meeting 
Centres of excellence in the candidate countries 
the economic and social needs of the 
regional environment. Examples of 
actions include the organisation of Euro­
pean conferences and seminars, welcom­
ing scientists from other countries, doc­
torate and postdoctorate training (includ­
ing study visits to other institutions) and 
twinning with other centres. 
This address book of excellence in the 
candidate countries is a valuable tool, 
opening the door to ensuring their 
research potential becomes an inherent 
part of the European Research Area and 
their participation in the future Frame­
work Programme. 
» Contact 
Jitka Vennekens, Research DG 
jitka.vennekens-capkoua@cec.eu.int 
(1) In addition to the ten Central and Eastern 
European countries, this group also includes the 
independent state of Cyprus. 
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BULGARIA 
SOFIA 
Bulgarian Information Society for the 21 st 
Century (B1S-21) 
Bulgarian Academy of Sciences - Central 
Laboratory for Parallel Processing 
Activities: information technologies in case of 
emergency and forecasting of damaging air 
pollution levels; reliability of nuclear reactors at 
the Kozloduy plant; multimedia applications for 
Slavonic languages. 
Contact: Ivan Dimov 
• ivdimov@bas.bg 
• saturn.acad.bg/ 
• www.bas.bg/clpp 
VARNA 
Centre for sustainable development and 
management of the Black Sea Region 
(CESUM-BS) 
Bulgarian Academy of Sciences - Institute of 
Oceanology 
Activities: approach to the environmental, eco­
nomic and social problems of the basin, which 
ranked among the most threatened expanses of 
water in the world. 
Contact: Snejana Moncheva 
• snejm@mail.varna.techno-link.com 
• cesum-bs@io-bas.bg 
• www.cesum-bs.io-bas.bg 
• www.io-bas.bg/ 
KOSTINBROO 
Bulgarian Centre of Excellence in Plant 
Biotechnology (Excellent Plant Biotec) 
AgroBiolnstitute - Centre for Plant Biotechnology 
Activities: applied genetic engineering in the 
field of plant biotechnology in collaboration 
with plant breeding institutes and stations in 
Bulgaria. 
Contact: Atañas Atanassov 
• geneng@mtel.net 
• www.geocities.com/PicketFence/Garden/ 
9151/ 
CYPRUS 
NICOSIA 
Centre of Excellence in Agriculture and 
Environment 
Agricultural Research Institute of Cyprus (ARICY) 
Activities: viruses in citrus fruits; molecular 
marker technology; integrated pest manage­
ment. 
Contact: loannis Papadopoulos 
• papado@arinet.ari.gov.cy 
• www.ari.gov.cy/aricy.htm 
Centre of Excellence on Computational 
Finance and Economics (HERMES) 
University of Cyprus - Center for Banking and 
Financial Research 
Activities: wide-risk management for large 
financial institutions; investment valuation and 
decision-making in a situation of uncertainty; 
macroeconomic modelling of emerging finan­
cial systems; performance of financial institu­
tions; the structure of household portfolios; 
computational financial modelling. 
Contact: Stavros Zenios 
• zenioss@yahoo.com 
• www.hermes.ucy.ac.cy 
CZECH REPUBLIC 
PRAGUE 
Advanced Research Centre for Cultural 
Heritage Interdisciplinary Projects (ARCCHIP) 
Institute of Theoretical and Applied Mechanics of 
the Czech Academy - Associated Research Cen-
tre for Historic Structures and Sites 
Activities: research on the problems of safe­
guarding European cultural heritage - espe­
cially in the EU candidate countries - and their 
inclusion in social and economic sustainability 
measures. 
Contact: Milos Drdacky 
• drdacky@itam.cas.cz 
• www.arcchip.cz/#About 
EU Centre of Excellence (MEDIPRA) 
Academy of Sciences - Institute of Experimental 
Medicine 
Activities: cell biology and pathology; neuro­
science; developmental toxicology and teratology. 
Contact: Eva Sykova 
• sykova@biomed.cas.cz 
• uemweb.biomed.cas.cz/lndex.htm 
Machine Intelligence Research and 
Application Centre for Learning Excellence 
(MIRACLE) 
Technical University in Prague - Faculty of Electri-
cal Engineering - Department of Cybernetics 
Activities: intelligent decision-making and control, 
computer vision and machine perception; data 
warehousing; industrial production system integra­
tion and production planning information systems. 
Contact: Vladimir Marik 
• marik@labe.felk.cvut.cz 
• cyber.felk.cvut.cz/MIRACLE/html/index.html 
ESTONIA 
TARTU 
Regional Centre of Excellence in New 
Functional Materials, their Design, Diagnos­
tics and Exploitation (ESTOMATERIALS) 
University of Tartu - Institute of Physics 
Activities: technologies for informatics; photon­
ics; medicine and environmental services. 
Contact: Kristjan Haller 
• haller@fi.tartu.ee 
• www.fi.tartu.ee/ce/introduction.htm 
Genetics for the next millennium 
(GENEMILL) 
Estonian Biocentre 
Activities: molecular and cell biology applied 
to medicine, genetics and environmental 
protection. 
Contact: Richard Villems 
• rvillems@ebc.ee 
• www.tymri.ut.ee/indexl.html 
HUNGARY 
SZEGED 
Regional Initiative for Improvement of 
Quality of Life through Research, Education, 
and Innovation in Molecular Cell Biology 
(BIOREGION-SZEGED) 
Hungarian Academy of Sciences - Biological 
Research Center (BRC) 
Activities: leading-edge research on understand­
ing the role of genes and gene products in the cell 
functions of microbes, plants and animals. 
Contact: Denes Dudits 
• dudits@nucleus.szbk.u-szeged.hu 
• www.szbk.u-szeged.hu/bioregion.html 
BUDAPEST 
BRIDGE (scholarship between East and West) 
Collegium Budapest - Institute for Advanced Study 
Activities: humanities, social sciences and the­
oretical natural sciences. 
Contact: Gábor Klaniczay 
• collegium.budapest@colbud.hu 
• www.colbud.hu/main/index.html 
EURO-NEURO-NETWORKS (Serving regional 
integration, higher education and welfare 
of society in the field of neuroscience) 
Hungarian Academy of Sciences - Institute of 
Experimental Medicine 
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Activities: networking in neuroscience; creat­
ing/establ ish ing the Central European Brain 
Research Tra in ing Centre; b r idg ing the gap 
between theoretical and applied neuroscience; 
transferring gene technology f rom West to East; 
increasing public awareness. 
Contact: Sylvester Vizi 
• esvizi@koki.hu 
• www.koki .hu/cntrofexc.html 
• www.koki .hu 
Centre of Excellence in Information Tech­
nology, Computer Science and Control 
(HUN­TING) 
Hungarian Academy ol Sciences ■ Computer and 
Automation Research Institute (SZTAKI) 
Activities: computer science; information tech­
no logy; appl ied mathemat ics; operat ions 
research and decision support systems; cellular 
non­linear networks; signal processing; artificial 
intelligence; intelligent manufacturing and busi­
ness processes. 
Contact: Peter Inzelt 
• inzelt@sztaki.hu 
• www.sztaki.hu/sztaki/coe/ 
Condensed Matter Research Centre 
(KFKI­CMRC) 
Hungarian Academy of Sciences ­ Research 
Institute for Solid State Physics and Optics 
Activities: study of solid and l iquid materials 
including their structure, properties and syn­
thesis. 
Contact: Agnes Buka 
• ab@power.szfki.kfki.hu 
• www.kfk i .hu/~cmrc 
Mathematics in information society 
(MATHIAS) 
Hungarian Academy of Science ­ Alfred Rényi 
Institute of Mathematics 
Activities: algebra; algebraic logic and geome­
try; analysis; combinatory and discrete mathe­
matics; convex and computat ional geometry; 
information theory; number theory; probabil i ty 
<incl statistics, etc. 
Contact: Dezsó Miklós 
• dezso@renyi.hu 
• www.renyi .hucl 
materials; semiconductors, insulator materials 
and thin f i lm structures; advanced dielectrics 
for mul t i funct ional applications; materials for 
ophtha lmology and vision science; solid­state 
ionics and devices. 
Contact: Andris Sternberg 
• stern@latnet.lv 
• www.cf i . lu. lv 
LITHUANIA 
VILNIUS 
Cell biology and lasers: towards new 
technologies CEBIOLA 
Vilnius University ­ UNESCO Associated Centre 
of Excellence for Research and Training in Basic 
Sciences 
Activities: b iophoton ics and quant ic l ight 
processes applied to biology; science and tech­
nology in optics. 
Contact: Benediktas Juodka 
• benediktas.juodka@cr.vu.lt 
• www.mif .vu. l t /unesco/ 
LATVIA 
RIGA 
Centre for advanced material research and 
technology (CAMART) 
University of Latvia ­ Institute of Solid State Physics 
Activities: computer mode l l ing of advanced 
POLAND 
WARSAW 
Advanced materials and structures (AMAS) 
Polish Academy of Sciences ­
Institute of Fundamental Technological Research 
(Centre of Mechanics and Information Technol­
ogy) 
Activities: mechanics of solids, structures, fluids 
and biomaterials; engineering acoustics includ­
ing non­destructive testing methods and ultra­
sonic appl icat ions in medic ine; in fo rmat ion 
technology; mechatronics; robotics and eco­
logically oriented construction engineering. 
Contact: Zenon Mroz 
• zmroz@ippt.gov.pl 
• www. ippt .gov.p l /amas/ 
Physics and Fabrication of Low Dimensional 
Structures for Technologies of Future Gen­
erations (CELD1S) 
Polish Academy of Sciences ­ Institute of Physics 
Activities: solid­state physics, and in particular 
the physics of semiconductors and magnetic 
materials on the nanometer scale. 
Contact: Jacek Kossut 
• kossut@ifpan.edu.pl 
• info.ifpan.edu.pl/celdis/ 
High pressure: a competitive method for 
the advancement of multi­disciplinary 
research and industrial applications 
(HIGH PRESSURE) 
Polish Academy of Sciences ­ High Pressure 
Research Center 
Activities: nitr ides techno logy for b lue­ l ight 
optoelectronics; nanocrystalline ultra­hard mate­
rials; pressure­induced structural changes in 
biological materials and food processing; appli­
cation of pressure­tuned laser diodes in medi­
c ine; synthesis of nanopowders under h igh 
pressure in the presence of microwaves. 
Contact: Wi t lod Lojkowski 
• wl@unipress.waw.pl 
• www.unipress.waw.pl 
Stefan Banach International Mathematical 
Centre of Excellence ( IMPAN­BC) 
Polish Academy of Sciences ­ Institute of 
Mathematics 
Activities: public­key cryptography and com­
putational number theory; informat ion theory 
and its applications to physics, finance and biol­
ogy; mathematical model l ing and analysis of 
cellular populat ions; non­ l inear systems and 
control ; mathematics of finance and stochastic 
cont ro l ; approx imat ion structures in Banach 
spaces; symplect ic singularit ies and appl ica­
tions; visual model l ing. 
Contact: Feliks Przytycki 
• feliksp@impan.gov.pl 
• www.impan.gov.pl /Excel lence 
Excellence in molecular b iotechnology­
getting European dimension (EMBEU) 
Polish Academy of Science ­ Institute of 
Biochemistry and Biophysics PAS 
Activities: molecular mode l l i ng of pro te in 
structures and pro te in ­p ro te in in teract ions; 
new variants of recombinant proteins; molecu­
lar studies on p lant deve lopment ; p lant ­
pa thogen interact ions; p lasmid genomics; 
appl ied fungal genet ics; m i tochondr ia l dis­
eases, etc. 
Contact: Wlodzimierz Zagorski­Ostoja 
• cemb@ibb.waw.pl 
• www. ibb.waw.p l /Centr ­Dosk/C­D­mol .h tml 
CRACOW 
Molecular Biotechnology ­ Integration of 
Education and Research (BIER) 
jagiellonian University ­ The Ian Zurzycki Insti­
tute of Molecular Biology 
Activities: biochemistry; biophysics; cell b iol­
ogy; p lant physio logy; m ic rob io logy and 
immunology. 
Contact: Kazimierz Strzalka 
• strzalka@awe.mol.uj.edu.pl 
• www.mol .u j .edu.p l /b ier .h tm 
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WROCLAW 
Centre for advanced manufacturing 
technologies (CAMT) 
Wroclaw University of Technology ­ institute of 
Production Engineering and Automation 
Activities: machine tools, robotics & assembly; 
design methodology; production engineering; 
manufacturing automation; manufacturing and 
quality. 
Contact: Jan Koch 
• jankoch@itma.pwr.wroc.pl 
• www.camt.pl 
OLSZTYN 
Food Safety ­ a challenge for processing 
food of plant origin (CENEXFOOD) 
Polish Academy of Sciences ­ Institute of Animal 
Reproduction and Food Research ­ Division of 
Food Science 
Activities: safe plant breeding for food process­
ing (influence of environmental factors, etc.); 
plant material as a source of functional products 
and ingredients; benefits and risks of food pro­
cessing; new methodologies to assess the 
wholesomeness of food. 
Contact: Halina Koslowska 
• haka@pan.olsztyn.pl office@pan.olsztyn.pl 
• www.pan.olsztyn.pl/cenexfood/ 
• www.pan.olsztyn.pl/indexO.html 
LODZ 
Designed molecules and macromolecules, 
their assemblies and biological functions 
(DESMOL) 
Polish Academy of Sciences Centre of Molecular 
and Macromolecular Studies 
Activities: asymmetric synthesis of complex 
organic molecules; NMR techniques of study­
ing molecular structure of biological interest; 
synthesis of macromolecules with desired 
topologies leading to materials for high­tech 
applications ranging from medical diagnostics 
to electronics; etc. 
Contact: Przemyslaw Kubisa 
• pkubisa@bilbo.cbmm.lodz.pl 
• www.cbmm.lodz.pl 
D 
ROMANIA 
BUCHAREST 
Function and Dysfunction Of Blood Vessels 
(BLOOD VESSELS) 
Romanian Academy ­ Institute of Cellular Biology 
and Pathology Nicolae Simionescu 
Activities: transcytosis in normal/pathological 
states; alterations in atherosclerosis and dia­
betes: their therapeutic control. 
Contact: Dr Maya Simionescu 
• simionescum@simionescu.instcellbiopath.ro 
• simionescu.instcellbiopath.ro/ 
European integration of the Romanian 
mathematical research activity 
(EURROMMAT) 
Romanian Academy ■ Institute of Mathematics 
Simion Stoilov 
Activities: operator theory and functional analy­
sis; operator algebras; differential equations and 
optimal control; mathematical physics and par­
tial differential equations; algebraic geometry; 
complex analysis; algebraic and differential 
topology; continuous media mechanics; poten­
tial theory. 
Contact: Radu Purice 
• purice@imar.ro 
• pompeiu.imar.ro/­eurrommat/Programme. 
php3 
• pompeiu.imar.ro/ 
Interdisciplinary research and applications 
based on nuclear and atomic physics 
(IDRANAP) 
Horia Hulubei National Institute for Physics and 
Nuclear Engineering 
Activities: nuclear methods for studying envi­
ronmental pollution components; applications 
of nuclear physics methods to biology and 
medicine; radioisotopes and radionuclide 
metrology; nuclear physics methods for study; 
analysis, and characterisation of materials; 
nuclei far from stability; decay modes; cosmic 
rays; and facilities. 
Contact: Dorin N. Poenaru 
• poenaru@ifin.nipne.ro 
• www.nipne.ro/ 
TULCEA 
Deltas and Wetlands (DELWET) 
Ministry of Water and Environment Protection ­
Danube Delta National Institute for Research 
and Development 
Activities: biodiversity conservation and sus­
tainable development of deltas and wetlands. 
Contact: Mircea Staras (Mr.) 
• mstaras@indd.tim.ro 
• www.indd.tim.ro/Excelenta/Centru.htm 
• www.indd.tim.ro 
Β 
SLOVAKIA 
ZILINA 
Centre for Transportation Research (CETRA) 
University of Zilina 
Activities: operation and economics of trans­
port; transport management; management sci­
ence and informatics; transport and transport 
infrastructure design and construction; 
mechanical engineering in transport; transport 
electronics; forensic engineering. 
Contact: Ladislav Skyva 
• cetra@utc.sk (optional: skyva@frtk.fri.utc.sk) 
• www.utc.sk/cetra 
• www.utc.sk/ 
BRATISLAVA 
Centre for reduction of negative impact of 
environmental factors on human health 
(STRESSNUTS) 
Slovak Academy of Sciences ■ Institute of 
Experimental Endocrinology 
Activities: resistance to negative consequences 
of mental and somatic stressors; cardiovascular 
risk in persons exposed to chronic stress condi­
tions; influence of chronic stress on mental 
health (drug treatment of depression and 
reduction of the incidence and severity of anxi­
ety and affective disorders); negative behav­
ioural responses (alcohol and drug abuse) to 
changes in social environment; diagnostic and 
therapeutic procedures in patients with hyper­
tension, obesity and diabetes; endocrine distur­
bances induced by nutritional factors and envi­
ronmental pollution. 
Contact: Daniela Jezova 
• ueenjezo@savba.savba.sk 
• nic.savba.sk/sav/inst/ueen/ce.htm 
SLOVENIA 
LJUBLJANA 
NMR spectroscopy in combination with 
computational methods on systems of bio­
logical interest (SLONNMR) 
National Institute of Chemistry ­ NMR Centre 
Activities: structural and theoretical chemistry; 
analytical chemistry and ecology; organic and 
inorganic materials; biotechnology and chemi­
cal engineering. 
Contact: Janez Plavec 
• janez.plavec@ki.si 
• www.ki.si/opisi.html 
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A floating 
An Icebreaker and 
scientific vessel 
operational at 
temperatures as low as 
minus 50°C, the 
Polarstern ¡s at sea 320 
days a year. The summer 
months find it in the 
Arctic Ocean and autumn 
and winter in Antarctica. 
An icebreaker weighing 11 820 tonnes and a multi-purpose vessel for geophysicists, 
oceanographers, climatologists and biologists - that's the Polarstern, the star of 
European polar research. RTD info reports on the latest feats of this tool of 
excellence and its scientific f itter, the Stiftung Alfred-Wegener- Insti tut für Polar- und 
Meeresforschung (AVVI) of Bremerhaven. 
Whether transporting heavy equipment to scientific sta­
tions in Antarctica, collecting plankton in the Arctic 
Ocean, measuring air movements in the upper atmos­
phere over the poles, or studying deep ocean currents 
under the ice floe, the Polarstern is equipped for the job. 
This unique vessel is both a powerful icebreaker and a 
genuine floating laboratory. 
The specialists in maritime hydrodynamics from the 
Hamburgische Schiffbau-Versuchsanstalt GmbH who 
designed this impressive vessel certainly thought big. Its 
14 000 kW engines - equivalent to a supertanker with four 
times its tonnage - drive two propellers which allow the 
vessel to cut through ice 1.5 metres thick at a speed of five 
knots an hour. 
With a crew of 55, the Polarstern is operational at tem­
peratures as low as minus 50°C. Since it was launched at 
the Kiel shipyards in 1982 it has been at sea 320 days a 
year, completing 27 missions in an almost unvarying rou­
tine: summer in the Arctic Ocean and autumn and winter 
in the Antarctic. 
A first-class scientific machine 
This activity at the two extremities of the globe is a con­
siderable maritime feat. 'If we want to arrive early enough 
to benefit from the southern summer, we must reach the 
continent of Antarctica at a time when the icebergs are 
particularly numerous along the coast, especially if we plan 
to penetrate the southern Weddel Sea, covered by an ice 
sheet,' explains glaciologist Hans Oerter.(') 
(1) All the scientists quoted work for the Alfred Wegener Institut 
(AWI). 
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A German tradition 
The Foundation Alfred Wegener Institute for Polar and 
Marine Research is by far the biggest European research 
centre in its field, with a staff of 700 and an annual bud­
get of €84 million. Set up in 1980 by the AWI of Bremer­
haven, the Foundation has also included the Potsdam 
Research Unit, since 1992, and the Biological Institute of 
Helgoland and the Wadden Sea research station at Sylt, 
since 1988. It is headed by geologist Jörn Thiede and is 
devoted to three disciplines: geology, climatology and 
marine biology, the latter comprising two departments, 
one for pelagic or surface species and the other for ben-
thic species which inhabit the ocean depths. In addition 
to the Polarstern, the AWI has a fleet of four océano­
graphie vessels and a permanent network of polar bases 
linked by satellite. 
The names of these bases alone evoke the rich history of 
German polar research: Koldewey, on the island of 
Spitzberg off the Greenland coast, is named after the nav­
igator and explorer Carl Koldewey (1837-1908) who led 
the first German expeditions to the North Pole; the Dall-
mann international station in Antarctica, which operates 
in the southern summer only, is not far from the terri­
tory explored in 1873 by the former whale hunter Eduard 
Dallmann (1830-1896); and the Neumayer permanent 
station, also in Antarctica, is named after George Von 
Neumayer (1826-1909) who headed the International 
Polar Commission from 1879. 
To find out more: http://www.awi-bremerhaven.de/ 
&3Ì 
During each southern summer, about 14 million square 
kilometres of the ice cap melt in Antarctica, triggering huge 
movements in oceanic water masses about which 
we still understand very little. 
phenomenon 
But the Polarstern is both a technical marvel and a powerhouse. 
Its first-class scientific equipment includes a meteorological 
observatory, deep-sea sounding devices to study marine cur­
rents, capture systems and a marine biology aquarium, seismo-
logical devices to study the geophysics of seabeds, and dredging 
devices to gather samples from the ocean depths. About 50 
researchers and technicians are employed in the vessel's nine lab­
oratories on each mission. 
Scientists from all over Europe are able to participate in a wide 
range of research projects thanks to the Polarstern. 'In 1998 
alone, our institute participated in 31 projects financed by the 
Union, and almost a quarter of the scientists who sailed on recent 
expeditions came from outside Germany,' notes Catherine Aude-
bert, who is responsible for the administration of European pro­
grammes at the AWI. 'Fourteen of these projects concerned 
marine biology and ten climate change and the polar ozone 
layer. The rest studied underwater geophysics, one of our institu­
tion's major specialities.' 
Continental drift 
Alfred Wegener (1880-1930) - to whom the AWI owes its 
name - was a key figure in this field of research. It was on 
observing the interlocking shapes of South America and Africa 
that he first formed the idea of continental drift. The hypothe­
sis initially met with somewhat ironic scepticism and it was not 
until the latter half of the 20th century that progress in geo­
physics confirmed his intuition: more than 200 million years 
ago, the earth did indeed consist of a single continent - Pangea 
- which later broke up. 
We now know that this drift is still occurring in the tectonic 
movements which are slowly separating the plates bearing the 
continents along 60 000 km of the huge ridge which runs 
beneath the waters of the Atlantic, Pacific and Indian Oceans. 
This impressive underwater mountain range, sometimes rising 
to several thousand metres in height, is the site of often intense 
but variable seismic activity, such as in Iceland. The inexorable 
· · 
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About 50 researchers board the Polarstern for each trip. 
Opposite, collecting ice samples and the sounding balloon to measure 
ozone levels during a mission in the Arctic. 
tectonic movements also create depressions or faults in 
the ridge which are like open 'cracks' through which 
molten magma can flow, adding to the earth's sub-
oceanic crust. 
Surprises at Gakkel Ridge 
Underwater geophysics is a subject of topical scientific 
interest. The Polarstern's latest expedition to the Arctic 
Ocean (31 July - 7 October 2001 ), on which it was accom­
panied by the US icebreaker Healy, was carried out under 
the Amore (Arctic Mid-Ocean Ridge Expedition) interna­
tional programme with the mission to study the 1 800 
km-long Gakkel Ridge. Lying at a depth of 5 000 metres 
below the polar ice cap, this northern segment of the 
North Atlantic Ridge had never been mapped; to do so 
was the principal mission of the Amore expedition. 
This underwater geography mission used seismographs 
on board the European icebreaker which are able to mea­
sure the speed at which signals emitted by a small artifi­
cial explosion on the surface are reflected back from the 
ocean floor. The faster they return, the shorter the dis­
tance. In this way it is possible to map the relief of the 
seabed. 
Seismographs are also able to detect natural explosions 
caused by underwater volcanic activity, and such readings 
have produced some notable surprises. Previous mea­
surements had established that the Eurasian and North 
American Plates, separated by the Gakkel Ridge, were 
moving apart in this region at the rate of just a few mil­
limetres a year (compared with almost 10 centimetres a 
year for the Pacific Ocean Ridge). This suggested reduced 
activity. But the Amore mission's recordings showed that, 
on the contrary, the Gakkel Ridge was a site of intense 
seismic activity. Dredging the seabed confirmed this 
observation by bringing to the surface basalt which is typ­
ical of active volcanoes. 
What could be the explanation for these seemingly con­
tradictory data? That would be the job of the geophysi-
cists. There is very keen interest in this kind of research 
Climate archives 
The thickness of the ice cap which covers Antarc­
tica has built up over several hundreds of thou­
sands of years. By drilling down into the ice to 
take samples it is therefore possible to obtain 
information on past air composition and climate. 
This is the aim of researchers with the European 
Project for Ice Coring in Antarctica (EPICA), sup­
ported by the Union and European Science Foun­
dation. 
A new drilling site has been selected at Dronning 
Maud Camp, about 500 kilometres from the Neu­
mayer base. An initial drilling operation to a 
depth of 100 metres was completed successfully 
during the southern summer of 2000/2001. Over 
the next five years researchers hope to be able to 
penetrate to a depth of between 600 and 800 
metres, enabling them to reconstitute the palaeo-
climate of 500 000 years ago. The Polarstern has a 
key logistic role in the EPICA programme. It trans­
ports equipment to the Neumayer base, which is a 
five to ten days journey by sea from the Dronning 
Maud Camp, and brings back the ice cores in 
refrigerated containers to Europe for analysis. 
http://www.antarctica.ac.uk 
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because, as geophysicist and mission member Wilfr ied 
Jokat explains, 'The Gakkel Ridge is the ideal site to test 
the forecasts of models of the expansion of the oceanic 
crust at the site of ultra-slow ridges.' 
Secrets of the deep 
Exploring underwater mountain ranges was not the only 
task for the Polarstern. Scientists on board the vessel -
which was making a return t r ip to the exact centre of the 
North Pole after a ten-year interval - were also able to 
study variat ions in ice thickness. Their results were 
awaited w i th particular interest as, dur ing the summer of 
2000, a US expedi t ion had described the existence of 
increasingly large 'water holes' (known as polynya) in the 
ice. This was interpreted as a possible effect of global 
warming. 
The Polarstern's f indings offer some reassurance. The fre­
quency and size of the polynya were found to be compa­
rable to the situation in 1991 . Al though the average thick­
ness of the ice floe has decreased from 2.5 metres to 2 
metres, this alone does not allow for any f i rm conclu­
sions. Any confirmation of change in the planet's cli­
mate must be based on the combined action of the 
atmosphere, the oceans and the ice masses. 
Every summer about 14 mill ion square kilometres of 
ice sheet melt in the Antarctic tr iggering huge move­
ments of oceanic water masses, about which we know 
very little. Researchers on board the Polarstern had the 
necessary equipment to study them. 'We use on-board 
probes, which are able to measure water temperature 
and conductivi ty, to tell us about salinity. This enables 
us to understand better the phenomenon known as 
Thermohaline Circulation whereby convect ion on a 
huge scale causes polar waters to affect the global cli­
mate , ' explains c l imato log is t Eberhard Fahrbach. 
Other devices are deposited at sea and then collected 
during the return voyage. Finally, certain icebergs are 
equipped w i th emit t ing buoys enabling their move­
ments to be monitored by satellite to provide valuable 
data on ocean currents. At a t ime when global warm­
ing is causing growing concern, the Polarstern is one of 
the tools enabl ing the secrets of c l imate change -
sometimes concealed deep beneath the polar ice caps 
- to be revealed. » 
Aurora Borealis 
This is the name of a new ice­
breaker which will spend all year in 
the mid-Arctic region. This scien­
tific vessel will make it possible to 
carry out unique and highly precise 
polar research, and to participate 
in the international océanographie 
drilling programme. The Aurora 
Borealis is an excellent example of 
the synergy between national 
research programmes. 
Europe in the cold 
Together with the French Institut 
Polaire, the AWI is the only Euro­
pean organisation working at both 
poles. Belgium, Italy and the 
United Kingdom also have research 
programmes in Antarctica, a 
region uniquely dedicated to scien­
tific exploration since the interna­
tional treaty was adopted in 1991. 
Denmark, Sweden and Finland 
concentrate on Arctic regions. 
Contacts 
► Catherine Audebert and 
Claudia Ratering, AWI 
caudebert@awi-bremerhaven.de 
cratering@awi-bremerhaven.de 
www.awi-bremerhaven.de 
Life at the heart of the ice 
Some surprising microscopic animals and algae, such as diatoms, live 
inside the ice floe. Under certain conditions these algae are so numerous 
that the ice takes on a brownish hue from their photosynthetic pigments. 
But how have they been able to adapt to such extreme living conditions? 
This is one of the subjects being studied by the AWI molecular biology 
research group, led by Linda Medlin: 'The Polarstern is an essential tool 
for collecting phytoplankton from polar waters,' she explains. 'We have 
learned how to grow a polar diatom species which will enable us to study 
its genetic expression. One of our aims is to understand what genes are 
expressed solely in the diatoms which live in these regions, and which 
ones allow them to withstand freezing.' 
Opposite, the geophysics 
station on board the 
Polarstern. With nine 
laboratories, the ship is 
equipped with a 
meteorological 
observatory, sensors to 
study ocean currents, an 
aquarium for marine 
biology and 
seismologicai and 
dredging devices. 
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resolve 
Since independence, India has concentrated on research to accelerate its development -
wi th impressive results in a number of high-tech fields. Yet, despite its growing importance 
as a centre of scientific excellence, India still has some way to go. We profile this enigmatic 
nation, a nation wi th which the European Union is establishing closer cooperation. 
A new kind of cooperation 
The signing of a scientific cooperation agreement 
marks a new high point in relations between India and 
Europe. Development assistance has given way to 
cooperation between equals for the mutual benefit of 
both parties 
'With this agreement we are looking at India in a radically new way. 
We have just signed up for projects of global importance with a full 
partner.' Daniel Descoutures, responsible for scientific links between 
Asia and the European Commission, stresses the new direction repre­
sented by the recent ratification of a scientific and technological 
cooperation agreement between the Union and India, signed in New 
Delhi in November 2001. 
This latest step deepens a cooperation which dates back to an initial 
agreement concluded in December 1993. Since then, India has par­
ticipated in many projects in partnership with European 
researchers, (1) but they were intended explicitly for developing coun­
tries receiving financial support from the Union. Most of the 55 Indo-
European projects implemented in this framework - allocated funds 
of €22.5 million - have been in traditional fields of cooperation such 
as health, agricultural production, food industries, sustainable man­
agement of resources - in particular the problematic issue of water -
and the impact of climate warming on farming practices. 
Between equals 
India, a genuine world centre in a number of high-tech and scientific 
fields, can no longer be viewed simply as a developing country. The 
new five-year renewable agreement is a partnership between equals 
on subjects of advanced research. Indian institutions, scientists and 
industrialists can participate in - or even coordinate - thematic pro­
jects under the Sixth Framework Programme, just like their European 
counterparts. In return, Union organisations and researchers can par­
ticipate in Indian programmes and generally enter into any form of 
cooperation and participate in existing programmes. Researcher 
exchanges, seminars and access to high-tech installations can all be 
organised. Furthermore, as the agreement states, this will be 'without 
transfer of funds'. 
Representatives of the two parties will sit on a management commit­
tee which will meet annually to propose research subjects, examine 
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Like all of India's major research centres, the Indian Insti­
tute of Science (IIS) in Bengalore and the Centre for Cel­
lular & Molecular Biology (CCMB) in Hyderabad are vir­
tual carbon copies of their European or US counterparts. 
Except for one 'detail': each has its own power plant and 
autonomous water supply. This is because the public net­
works are unable to guarantee continuous access to these 
basic resources. The contrast is characteristic of India 
itself, a nation which has reached the highest interna­
tional level in some scientific fields while in other areas it 
is lagging seriously behind in development. 
From planned research... 
On gaining independence in 1947, Nehru's India turned 
to science to meet national needs and began to build up 
or renew its scientific and university infrastructure. In this 
planned economy, it was the federal government which 
decided priorities as it sought to meet huge needs in the 
fields of agriculture, health, energy, education, industry, 
and also military expenditure. 
Major investments were made in electronics, material sci­
ences, atomic energy and space technology. 1974 
brought the first underground explosion of a nuclear 
device, soon followed by the launch of the first artificial 
satellites for scientific, meteorological and telecommuni­
cation purposes. The range of specialities - nanomaterials, 
computing, pharmacy, microbiology, meteorology, neu­
rosciences, seismic research, etc. - continued to broaden 
while the structures remained unchanged. Universities 
and scientific institutes depended almost entirely on gov­
ernment money, often through government programmes 
with virtually no contacts with an industry which did not 
invest in R&D. 
... to partnership with industry 
It was not until July 1991, when the government 
embarked on major economic reforms and liberalised 
trade and investment, that cooperation between industry 
and the universities could really take off. Between 1988 
and 1 994 research or expertise contracts between indus­
try and the Council of Scientific and Industrial Research 
(CSIR)'1) tripled in value. It was now not unusual for a uni­
versity professor to take a year's sabbatical to help a pri­
vate firm set up its research centre. Business incubators in 
fields such as biotechnology, data processing and phar­
macy flourished around university campuses. Major uni­
versity towns created technology parks where new and 
innovative companies could enjoy fiscal benefits as well as 
a reliable infrastructure (electricity, water, telecommuni­
cations) free from the burdens of Indian administrative 
red tape. Dr Matha, director of the prestigious IIS in Ben-
galore, believes that this was 'undeniably the result of the 
change in Indian government policy in the early 1990s'. 
(1) The equivalent of agencies such as the CNRS in France or the 
MPG in Germany. 
Internet 
Three excellent sites to find out 
more about science and technology 
in India 
I www.meadev.nic.in/science/intro.htm 
I www.indusscitech.net/ 
I www.research-in-india.8m.com/ 
research.html 
Published by the National Science 
Academy, New Delhi, 2001 
proposals and launch calls for tender. Cooperation in fields such as 
nanotechnologies, advanced materials, civil aviation and computer 
software can all be expected. 
Science and diplomacy 
'The agreement was generally inspired by the conclusions of the Lis­
bon European Summit which stressed the importance of knowledge 
for the 21st century economy... which is very much in line with the 
beliefs expressed many times by Indian politicians,' continues Daniel 
Descoutures. 'Clearly Europe will not be able to create its own 
research area without drawing on external expertise. Also, some key 
questions for science and society - such as genetically modified 
organisms or climate change - require a global response. Countries 
such as China, Russia, the United States - and India - must be 
involved. These subjects require a joint scientific base.' 
In addition to the purely scientific benefits, there are also diplomatic 
considerations. India is comparable in size to China and is the world's 
largest democracy. It is a member of the WTO and has experienced 
several years of sustained growth. The conclusion? 'India is rapidly 
becoming a key world player and Europe needs strategic allies within 
international forums which discuss the rules of international trade, 
intellectual property agreements and the Kyoto Protocol.' The princi-
ple of mutual interest, which is stressed on a number of occasions in 
the text of the agreement, also addresses the realities of the world. 
(1) In the framework of the European INCO (1994-98) and INC02 (1998-2002) 
programmes - see www.cordis.lu/inco2/src/wp_en.htm 
Contact: Daniel Descoutures, Directorate-General for Research 
daniel. descoutures@cec. eu. int 
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A government 
department 
specialising in 
biotechnology 
embodies the 
government's 
resolve to 
concentrate on the 
life sciences. 
f 
Indian Silicon Valley 
The success of the Indian software industry is a perfect example 
of Indian efficiency, the level of excellence earning the country 
around 15 billion dollars in export revenue in 1999. After disap­
pointing attempts at manufacturing computer hardware, India 
decided to concentrate on developing software solutions, a field 
in which it soon excelled, thanks to its long tradition of mathe­
matics. 'We managed to develop efficient programmes despite 
inefficient computers,' researchers like to say. 
Over recent years these technologies (which 'restored pride to 
India', to quote R.A. Mashelkar, director of the CSIR) have been 
the subject of a specific national policy, starting in 1985 with the 
lowering of customs duties on software and hardware and fol­
lowed by 'forced' computerisation of the public sector and the 
creation of a specialised government department. The depart­
ment's official mission is to 'make India a superpower in the field 
of information technology by 2008'. A company such as Infosys 
is testimony to this resolve. This Bengalore software and com­
puter consultancy firm symbolises India's ability in this field, 
recording almost 99% of its turnover with foreign customers, 
including 70% in the United States and 20% in Europe. 
This international reputation in the field of high technologies 
must not, however, be reason to forget the huge contrast 
between the success of Indian science, on the one hand, and the 
unsatisfied fundamental needs of Indian society, on the other. 
The population has reached the billion mark and is continuing 
to grow. The steady increase in agricultural production achieved 
by the 'green revolution' of the 1 960s has ceased after having 
caused huge ecological damage. The environment is also suffer­
ing from the effects of uncontrolled urbanisation. 
Faith in life sciences 
Biotechnologies can bring solutions in the fields of health (diag­
nostics and vaccinations), agriculture (productivity, resistance 
to drought and pests, livestock health) and the environment 
(water treatment/purification). Back in 1986, India was one of 
the first countries to put its faith in what was still an emerging 
sector by setting up a specialised government department, as it 
had done previously for space and information technologies. 
Today, India has built up some very promising potential in 
the life sciences. But is it perhaps about to follow the example 
of information technology in becoming an 'off-shore' sector, 
or will it be the spearhead of sustainable endogenous develop­
ment? I 
Two-way traffic 
Excellent universities, but too few posts for its 
scientists... The Indian brain drain to the 
United States - and more recently Europe also 
- shows no sign of slowing. Yet, at the same 
time, many multinationals are being attracted 
to India for its intellectual resources, moti­
vated workforce and competitive salaries. 
Companies such as Monsanto, General Elec­
tric, Intel, Microsoft, IBM, Siemens and 
Dupont have all set up research and develop­
ment centres in India over recent years. So 
much so that Indian researchers have no hes­
itation in describing their country as the 
future 'world centre for R&D'. 
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phone: friend or foe? 
Three out of five Europeans use their mobile phones every day. The question is: 
Are the electromagnetic waves emit ted by these phones and their base stations 
harmful to health? There is no scientific evidence to confirm this but, true to the 
principle of 'better safe than sorry', a number of research projects are now trying 
to confirm that they are hazard-free. 
Without knowing or noticing it, we have long been immersed in 
a veritable electrosmog covering a very wide frequency spec­
trum. These emissions come from televisions, microwave ovens 
and electric shavers as well as surveillance systems, computers or, 
quite simply, the electricity grid. More recently, an increasingly 
constant companion has been making its contribution to the 
electrosmog: the mobile telephone. 
Does constant and increasing exposure to this kind of radiation 
constitute a danger? No, the experts have always claimed, as the 
intensities of these fields are far too low to raise the temperature 
of human body organs - and below this level no harmful effect 
has ever been shown. Mobile or cell phones, for example, emit 
only very weak microwave radiation (less than 2 watts). However, 
unlike other devices, they create an electromagnetic field in the 
immediate vicinity of the ear and brain. 
What are the biological effects? 
Initial suspicions mainly concerned the carcinogenic potential of 
microwaves. However, the many research projects on the sub­
ject have to date provided no evidence of any link between nor­
mal exposure to the radiation emitted in radiofrequencies by 
mobile phones and the appearance of malignant tumours.'1' 
But cancer is not the only health risk evoked in connection with 
mobile phones. In France, the recent Zmirou report«2' stresses 
that 'scientific data indicate in a way which it is difficult to dis­
pute the existence of varied biological effects (electroen­
cephalogram profile, reaction time) for energy levels which do 
not cause an increase in local temperature', without being able 
to conclude that this poses any threat to health. Various symp­
toms - memory or attention problems, tiredness, headaches, 
hearing problems - are sometimes reported. In some individuals 
these seem to correspond to a kind of 'electromagnetic hyper­
sensitivity' attributable to the intense use of mobile phones 
or proximity to the transmitter masts which serve as their base 
stations. 
Targeting ultra-low frequencies 
In another scientific report commissioned by the European Par­
liament/3) Dr Gerard Hyland of the Department of Physics at 
Warwick University concludes that European recommendations 
do not go far enough as they are based solely on the thermal 
(7) This view is corroborated in particular by the World Health Organisation, 
the British authorities (Stewary report) and the British Medical Association. 
(2) Available at www.sante.gouv.fr/ 
(3) Available at www.carolinelucasmep.org.uk/ 
publicationslpdfs_and_wordlstoa.doc 
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Given present 
uncertainties 
about mobile 
telephones, it is 
better not to 
leave them too 
often in the 
hands of 
children. 
Some European 
research 
projects... 
Interphone 
This is an epidemiological study 
covering 13 countries and launched 
in 2000 by the Centre international 
de recherche sur le cancer (CIRC) in 
Lyons.* Allocated € 4 million in fund­
ing and coordinated by Dr Elisabeth 
Cardis, this project is examining the 
correlation between the use of mobile 
phones and the appearance of 
tumours of the brain, auditory nerve 
or parotid gland (salivary gland 
located in the cheek). Results are due 
to be published in 2004. 
"See RTD info n°27, 
September2000 
Contact: Elisabeth Cardis 
cardis@iarc.fr 
· · 
influences of electromagnetic fields. He believes that brain 
activity and the neuroendocrine system could also be 
adversely affected by the pulsed microwave signals emit­
ted by mobile phones. 
A number of studies are now looking at this largely unex­
plored field of pulsed radiation. Emitted at extremely low 
frequencies, it is produced by televisions and high-tension 
lines as well as mobile phones. Scientists are wonder ing if 
these waves could have an effect on the electromagnetic 
field (generated by the movement of calcium, magne­
sium and other ions) of our own body. In which case, 
when exceeding a certain level of intensity could this phe­
nomenon increase the probabil i ty of child leukaemias? 
The World Health Organisation (WHO) opts for prudence 
in recommending that pulsed radiation should be consid­
ered as potentially carcinogenic for very young individu­
als and advocates further research. 
Reference system required 
'Everybody accepts that at high levels there is a very real 
and perhaps serious biological effect. But at very low lev­
els there is, as yet, no evidence at all of harmful effects. 
However, this does not remove a degree of uncertainty as, 
if there are effects, their incidence is very low and very dif­
ficult to distinguish f rom other factors. To obtain the suf­
ficient resolution to detect these effects requires large-
scale epidemiological studies, such as the Interphone pro­
ject which meets these requirements,' explains Laurent 
Bontoux, expert at the Commission's Joint Research Cen­
tre (JCR). The Union is currently f inancing a number of 
research projects in this f ield'4 ' , but they are relatively 
recent and must be continued in the long term before 
their results can be usefully evaluated. The results of the 
vast In terphone ep idemio log ica l study are the most 
eagerly awaited. 
To complement these European research projects, the JCR 
is trying to create a scientific and technological reference 
system as a means of quantifying the radiation emitted by 
mobile phones and their base stations, so that scientists 
wil l at least be speaking the same language. 'The majority 
of the research participants will be gett ing together to 
define common standards w i th which to measure expo­
sure to this kind of radiation,' continues Laurent Bontoux. 
'This is an absolute precondit ion for an increasingly in-
depth evaluation of health risks.' 
t Contacts: 
Callum Searle, Research DC 
callum.searle@cec.eu.int 
Laurent Bontoux, Joint Research Centre 
laurent.bontoux@jrc.org 
COST coordination (4) Under the 'Environment and health' key action. 
The pan-European COST initiative, which 
coordinates national research projects in this 
field, has already published two reports on the 
current state of knowledge of risks linked to 
exposure to electromagnetic fields. The overall 
conclusions were that there is, at present, no 
evidence of damaging effects on health, 
although they did identify new areas of 
research for a more rigorous risk analysis. 
Last September the COST 281 Action was 
launched to study the effects of electromag­
netic fields (EMF) linked to the new UMTS 
(third generation of mobile phones), Blue­
tooth (the infra-red communication standard 
for mobile phones) and WLAN (wide band net­
work using radiofrequencies) technologies. 
About 50 researchers are working on this pro­
gramme which covers 18 countries at an esti­
mated cost of €75 million over five years. Its 
first action was to organise a conference com­
prising US, Japanese and Korean scientific bod­
ies, last October. 
'As the technology is evolving very quickly, it 
is essential to have a good understanding of 
the interaction of biophysical and biological 
mechanisms with electromagnetic fields so as 
not to have to start from zero with each tech­
nological innovation,' explains Peter Wintlev-
Jensen who supervises this research at the 
Information Society DG. 'Also, the effects this 
research is studying are so difficult to evaluate 
that extensive studies based on a large statisti­
cal base are essential to reaching any credible 
conclusions.' 
In addition to this new initiative, COST also 
serves as a discussion forum for researchers, 
industry and the public authorities, and is set­
ting up working groups to look at more spe­
cific questions, such as effects of exposure on 
children. 
cost, cordis. lu/src/action_detail. dm ?action=281 
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Better safe than sorry 
Perform-A 
Each country is responsible for setting its own permissible levels of 
exposure to electromagnetic fields. Most of these national standards 
take their lead from the W H O recommendations. 
WHO/ICNIRP standards 
Frequency 
Public 
exposure limits 
Occupational 
exposure limits 
European power 
frequency 
Electric 
field 
(V/m) 
50 Hz 
5 000 
10 000 
Magnetic 
field 
(μΌ 
50 Hz 
100 
500 
Mobile phone 
base station 
Power 
density 
(W/m') 
900 MHz 
4,5 
22,5 
Power 
density 
(W/rrY) 
1.8 GHz 
9 
45 
Microwave 
frequency 
Power 
density 
(Wlrtf) 
2.45 GHz 
10 
Not attributed 
Five examples of 
standards 
recommended by the 
WHO, based on 
scientific evaluations by 
the International 
Commission on Non-
Ionising Radiation 
Protection (ICNIRP). 
The WHO estimates are based on the scientific evaluations 
carried out by the International Commission on Non-Ion­
ising Radiation Protection (ICNIRP). In 1996, fol lowing 
fears linked in particular to the growing use of mobile 
phones, the two organisations decided to launch a major 
research programme known as the International EMF Pro­
ject. The aim was to take stock of the current state of 
knowledge and data collected in this complex field by the 
many scientific agencies and institutions wor ldwide. 
Five examples of recommended standards were subse­
quently drawn up (see table). These give limits for the 
general public and for occupational exposure (for which 
the permissible levels can be higher). These thresholds are 
based on the principle of prudence. Exceeding them, cer­
tainly if only temporarily, does not mean there will be an 
inevitable damage to health but rather that one is enter­
ing an area which could possibly present certain risks. 
GSM and SAR 
For emissions linked to the specific case of mobile tele­
phone use, the ICNIRP has defined a complex standard 
known as the Specific Absorption Rate (SAR), which indi­
cates the risk of heating to which the upper part of the 
body is exposed. Depending on wave frequency and the 
composition of the materials the waves cross, telephone 
power and operating mode and the position of the base 
station, the SAR should not exceed 2 watts per kilo on 
average for the head and trunk. 
A 1999 EU Council recommendation adopted this stan­
dard as a basis in seeking to l imit exposure of the popula­
t ion to electromagnetic fields wi th in the 0 GHz to 300 
GHz range/1 > Last October, the Scientific Committee on 
Toxicity, Ecotoxicity and the Environment (CSTEE) con­
sidered that given the present state of knowledge there 
was no justification for revising present exposure limits.'2* 
According to this opinion, 'subjective symptoms affecting 
some individuals possibly exist, but not enough informa­
tion is available on the levels of exposure producing such 
effect or the features underlying individual susceptibility'. 
The Commit tee did not, however, give an opinion on any 
link between exposure to electromagnetic fields and cases 
of leukaemia in children. \ 
► Reference site 
www.who.int/peh-emf/EMFversions.htm 
(1) In the interests of prudence, some Member States have adopted 
lower values than those recommended by the WHO for the exposure 
of their populations to base stations. 
(2) This opinion can be consulted at 
europa.eu.int/comm/food/fs/sc/sct/outl 28_en.pdf 
This project, co-financed by the 
Union and industry, is studying the 
carcinogenic effects of radiofre-
quencies on animals. Rats and mice 
are being exposed to GSM 900 and 
1800 MHz signals in the laborato­
ries of the Swiss Federal Institute of 
Technology in Zurich (Switzerland) 
and at the Fraunhofer ITA (Institute 
of Toxicology and Aerosol Research) 
in Germany. Meanwhile, laboratories 
in Vienna and Turin are trying to 
reproduce and confirm previous 
experiments - notably by Dr Rapa-
choli who. in 1997, showed an 
increase in lymphoma incidence in a 
line of hypersensitive mice exposed 
to GSM waves for 18 months. 
Contact: Clemens Dasenbrock, 
Fraunhofer-ITA 
dasenbrock@ita.flig.de 
Reflex 
In vitro experiments are being 
conducted at 11 European 
laboratories to demonstrate lhe 
action of microwaves on cellular 
processes - in particular, 
genotoxic effects, 
cellular differentiation, gene 
expressions-or the immune 
system. 
Contact: Franz Adlkofer, 
Foundation for Behaviour and 
Environment, Munich 
prof.adlhofer@verum-foundalion.de 
Ramp 2001 
Research on the non-thermic bio­
logical effects of microwaves on 
nerve cells, for both GSM mobiles 
and the future third generation of 
mobile phones. 
Contact: Bruno Bianco, 
University of Genoa 
white@dibe.unige.it 
Guard 
Study of the effects of mobile 
phones on hearing and the 
associated cognitive functions in 
animals and man. 
Contact: Paolo Ravazzani. National 
Council fur Scientific Research 
paolo.ravazzani@polimi.it 
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Technology without borders 
It is not always easy for high-tech SMEs to gain a foothold in foreign 
markets or to f ind partners outside their own country. To help them to 
make a success of international cooperation, the Innovation Relay 
Centres (IRCs) offer a network of experts active throughout Europe. 
The Berlin printer Oktoberdruck AG 
wanted to digitise its production line. 
Thanks to an 'exploratory grant' from the 
Esprit programme it managed to locate a 
small Greek software firm, Zenon SA (a 
partner in the European D-Print project), 
which had developed an integrated digi­
tal printing concept and was seeking to 
distribute it on the European market. 
The two firms signed a technology trans­
fer agreement which was perfectly suited 
to Oktoberdruck's needs. In 1999, it 
invested €500 000 in its pre-press depart­
ment. Since then it has invested nearly 
€3 million in new machines and a com­
pany-wide integration of the computer 
network, thereby successfully managing 
the changeover process. 
Finding one another 
There are many similar opportunities for 
European partnerships, but few ever see 
the light of day. This is quite simply 
because the potential partners never 
meet, or if they do they fail to conclude 
what is often a very complex technologi­
cal cooperation agreement. 
The network of Innovation Relay Centres 
(IRCs), supported by the Union's Fifth 
Framework Programme, aims to increase 
the prospects of success for such part­
nerships. With about 1 000 technology 
experts at 250 European offices in the 
Union and candidate countries, it pro­
vides effective logistical support for tech­
nology transfers between SMEs on a scale 
which is rarely seen anywhere else in the 
world. 
Each IRC is deeply rooted in the local 
industrial fabric and research networks 
while at the same time connected up, via 
intranet, to a trans-European network 
with extensive databanks at its disposal. 
Working closely together with their 
clients, the IRC experts draw up details of 
technology demand and supply and cir­
culate them throughout the network. 
Rapid response 
Potential contacts are often identified 
very quickly. After that the future partners 
can communicate directly. Their respec­
tive IRCs remain on hand if their services 
are needed, such as to provide a techni­
cal, economic - for example, to raise 
finance - or legal evaluation. 
Oktoberdruck's first contact was with the 
Berlin Chamber of Commerce which 
directed it to the IRC for northern 
Germany which was itself in contact 
with a Greek IRC which knew Zenon. 'We 
assisted the two firms during their first 
meetings and in negotiating their 
contract,' explains Eckhard Behrendt, 
adviser at the German IRC. His Greek col­
league provided similar assistance to his 
client, especially on matters of intellectual 
property. 
Downstream 
of European programmes 
'Special interest groups' comprising sev­
eral IRCs focusing on technological spe­
cialities (aerospace, nano- and microtech­
nologies, new materials, biotechnologies, 
etc.) are a second strategic aspect of the 
IRC network. They provide a link between 
the 'Innovation cells' which, within Euro­
pean programmes, are responsible for 
promoting the exploitation of the results 
achieved by Union-backed research. 
For the Hanover Biotechnica Fair (DE) in 
October 2001, for example, the network 
set up the CellExploit project in partner­
ship with the 'innovation cell' of the Cell 
Factory key action (Quality of Life Pro­
gramme). Detailed prospecting by the 
Biotechnology Special Interest Group 
resulted in the production of a very prac­
tical multimedia catalogue of technologi­
cal opportunities. > 
» Contacts 
M. de Carli. IRC-IRE Central Unit 
Fax.+352 441012 2055 
m.decarli@ircnet.lu 
ire.cordis.lu/ 
P. Piichner, IRC South Germany/Deutsch Schweiz 
puechner@steinbeis-europa.de 
www.cellexploit.net/ 
